<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:07:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9942570" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9942570</identifier>
        <datestamp>2023-02-22</datestamp>
        <setSpec>msphere</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">mSphere</journal-id>
              <journal-id journal-id-type="iso-abbrev">mSphere</journal-id>
              <journal-id journal-id-type="publisher-id">msphere</journal-id>
              <journal-title-group>
                <journal-title>mSphere</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2379-5042</issn>
              <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
                <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9942570</article-id>
              <article-id pub-id-type="pmcid">PMC9942570</article-id>
              <article-id pub-id-type="pmc-uid">9942570</article-id>
              <article-id pub-id-type="pmid">36622252</article-id>
              <article-id pub-id-type="pmid">36622252</article-id>
              <article-id pub-id-type="publisher-id">00585-22</article-id>
              <article-id pub-id-type="doi">10.1128/msphere.00585-22</article-id>
              <article-id pub-id-type="publisher-id">msphere.00585-22</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="biological-terms">
                  <compound-subject>
                    <compound-subject-part content-type="code">public-health</compound-subject-part>
                    <compound-subject-part content-type="label">Public Health</compound-subject-part>
                  </compound-subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7631-6760</contrib-id>
                  <name>
                    <surname>Haddad</surname>
                    <given-names>Lisa B.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <email>lhaddad@popcouncil.org</email>
                  <!--<xref ref-type="other" rid="cr1 cr2 cr3"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tang</surname>
                    <given-names>Jennifer H.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <xref rid="aff4" ref-type="aff">
                    <sup>d</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr4 cr5 cr6"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Nicole L.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr7 cr8"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kourtis</surname>
                    <given-names>Athena P.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr9 cr10 cr11"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chinula</surname>
                    <given-names>Lameck</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <xref rid="aff4" ref-type="aff">
                    <sup>d</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr12 cr13"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Msika</surname>
                    <given-names>Albans</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr14"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tegha</surname>
                    <given-names>Gerald</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr15"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hosseinipour</surname>
                    <given-names>Mina C.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <xref rid="aff6" ref-type="aff">
                    <sup>f</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr16 cr17"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nelson</surname>
                    <given-names>Julie A. E.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>g</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr18"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hobbs</surname>
                    <given-names>Marcia M.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>g</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr19"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gajer</surname>
                    <given-names>Pawel</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">
                    <sup>h</sup>
                  </xref>
                  <xref rid="aff9" ref-type="aff">
                    <sup>i</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr20 cr21 cr22 cr23"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0851-2233</contrib-id>
                  <name>
                    <surname>Ravel</surname>
                    <given-names>Jacques</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">
                    <sup>h</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr24 cr25 cr26 cr27"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5199-3004</contrib-id>
                  <name>
                    <surname>De Paris</surname>
                    <given-names>Kristina</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>g</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr28 cr29 cr30 cr31 cr32"/>-->
                </contrib>
                <aff id="aff1">
                  <label>a</label>
                  <addr-line>Center for Biomedical Research, Population Council, New York, New York, USA</addr-line>
                </aff>
                <aff id="aff2">
                  <label>b</label>
                  <addr-line>University of North Carolina at Chapel Hill, Department of Obstetrics &amp; Gynecology, Chapel Hill, North Carolina, USA</addr-line>
                </aff>
                <aff id="aff3">
                  <label>c</label>
                  <addr-line>UNC Project-Malawi, Kamuzu Central Hospital, Lilongwe, Malawi</addr-line>
                </aff>
                <aff id="aff4">
                  <label>d</label>
                  <addr-line>Malawi College of Medicine, Department of Obstetrics &amp; Gynecology, Blantyre, Malawi</addr-line>
                </aff>
                <aff id="aff5">
                  <label>e</label>
                  <addr-line>U.S. Centers for Disease Control and Prevention, Division of HIV Prevention, Atlanta, Georgia, USA</addr-line>
                </aff>
                <aff id="aff6">
                  <label>f</label>
                  <addr-line>University of North Carolina at Chapel Hill, Division of Infectious Diseases, Chapel Hill, North Carolina, USA</addr-line>
                </aff>
                <aff id="aff7">
                  <label>g</label>
                  <addr-line>University of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, North Carolina, USA</addr-line>
                </aff>
                <aff id="aff8">
                  <label>h</label>
                  <addr-line>Institute for Genome Sciences, University of Maryland School of Medicine, Health Sciences Facility III, Baltimore, Maryland, USA</addr-line>
                </aff>
                <aff id="aff9">
                  <label>i</label>
                  <addr-line>Department of Microbiology and Immunology, University of Maryland School of Medicine, Health Sciences Facility III, Baltimore, Maryland, USA</addr-line>
                </aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <role>Editor</role>
                  <name>
                    <surname>Rao</surname>
                    <given-names>Krishna</given-names>
                  </name>
                  <aff>University of Michigan—Ann Arbor</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <fn fn-type="COI-statement">
                  <p>The authors declare no conflict of interest.</p>
                </fn>
              </author-notes>
              <pub-date publication-format="electronic" date-type="pub">
                <day>9</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="collection">
                <season>Jan-Feb</season>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>8</volume>
              <issue>1</issue>
              <elocation-id>e00585-22</elocation-id>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <ali:free_to_read start_date="2023-01-09"/>
                <license>
                  <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                  <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="msphere.00585-22.pdf"/>
              <abstract>
                <title>ABSTRACT</title>
                <p>Important questions remain on how hormonal contraceptives alter the local immune environment and the microbiota in the female genital tract and how such effects may impact susceptibility to HIV infection. We leveraged samples from a previously conducted clinical trial of Malawian women with (<italic toggle="yes">n</italic> = 73) and without (<italic toggle="yes">n</italic> = 24) HIV infection randomized to depot medroxyprogesterone acetate (DMPA) or the levonogestrel implant in equal numbers within each group and determined the effects of these hormonal contraceptives (HCs) on the vaginal immune milieu and the composition of the vaginal microbiota. Longitudinal data for soluble immune mediators, measured by multiplex bead arrays and enzyme-linked immunosorbent assays (ELISAs), and vaginal microbiota, assessed by 16S rRNA gene amplicon, were collected prior to and over a period of 180 days post-HC initiation. DMPA and levonogestrel had only minimal effects on the vaginal immune milieu and microbiota. In women with HIV, with the caveat of a small sample size, there was an association between the median log<sub>10</sub> change in the interleukin-12 (IL-12)/IL-10 ratio in vaginal fluid at day 180 post-HC compared to baseline when these women were classified as having a community state type (CST) IV vaginal microbiota and were randomized to DMPA. Long-lasting alterations in soluble immune markers or shifts in microbiota composition were not observed. Furthermore, women with HIV did not exhibit increased viral shedding in the genital tract after HC initiation. Consistent with the results of the ECHO (Evidence for Contraceptive Options and HIV Outcomes) trial, our data imply that the progestin-based HC DMPA and levonorgestrel are associated with minimal risk for women with HIV. (This study has been registered at <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> under registration no. NCT02103660).</p>
                <p><bold>IMPORTANCE</bold> The results of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial, the first large randomized controlled clinical trial comparing the HIV acquisition risk of women receiving DMPA, the levonorgestrel (LNG) implant, or the copper intrauterine device (IUD), did not reveal an increased risk of HIV acquisition for women on any of these three contraceptives. Our study results confirm that the two different progestin-based hormonal contraceptives DMPA and levonogestrel will not increase the risk for HIV infection. Furthermore, DMPA and levonogestrel have only minimal effects on the immune milieu and the microbiota in the vaginal tract, attesting to the safety of these hormonal contraceptives.</p>
              </abstract>
              <kwd-group>
                <title>KEYWORDS</title>
                <kwd>HIV</kwd>
                <kwd>inflammation</kwd>
                <kwd>cytokines</kwd>
                <kwd>progestin contraception</kwd>
                <kwd>levonorgestrel implant</kwd>
                <kwd>depot medroxyprogesterone acetate injectable</kwd>
                <kwd>microbiome</kwd>
                <kwd>contraception</kwd>
                <kwd>progestin</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant" id="award1">
                  <funding-source id="GS1">
                    <institution-wrap>
                      <institution>Bill and Melinda Gates Foundation (GF)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000865</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>OPP1090837</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Ravel</surname>
                      <given-names>Jacques</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award2">
                  <funding-source id="GS2">
                    <institution-wrap>
                      <institution>HHS | Centers for Disease Control and Prevention (CDC)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000030</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U48DP00194</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kourtis</surname>
                      <given-names>Athena P.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Haddad</surname>
                      <given-names>Lisa B.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Tang</surname>
                      <given-names>Jennifer H.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Davis</surname>
                      <given-names>Nicole L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award3">
                  <funding-source id="GS3">
                    <institution-wrap>
                      <institution>HHS | Centers for Disease Control and Prevention (CDC)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000030</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>200-2015-M-63021</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kourtis</surname>
                      <given-names>Athena P.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Haddad</surname>
                      <given-names>Lisa B.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Tang</surname>
                      <given-names>Jennifer H.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Davis</surname>
                      <given-names>Nicole L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award4">
                  <funding-source id="GS4">
                    <institution-wrap>
                      <institution>HHS | NIH | Office of Extramural Research, National Institutes of Health (OER)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006955</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30-AI50410</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Hobbs</surname>
                      <given-names>Marcia M.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>Julie A. E.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Hosseinipour</surname>
                      <given-names>Mina C.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Paris</surname>
                      <given-names>Kristina De</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award5">
                  <funding-source id="GS5">
                    <institution-wrap>
                      <institution>HHS | National Institutes of Health (NIH)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1K01-TW009657-01</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Tang</surname>
                      <given-names>Jennifer H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <count count="6" count-type="supplementary-material"/>
                <fig-count count="7"/>
                <table-count count="5"/>
                <equation-count count="0"/>
                <ref-count count="83"/>
                <page-count count="19"/>
                <word-count count="11730"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January/February 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Some observational studies had suggested that hormonal contraceptives, specifically depot medroxyprogesterone acetate (DMPA), may increase a woman’s susceptibility to HIV infection (<xref rid="B1" ref-type="bibr">1</xref>). Systematic reviews of observational studies estimated that women on DMPA compared to women not using hormonal contraceptive (HC) methods had a 40 to 50% increased risk of HIV acquisition (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). However, numerous other studies could not find an association between DMPA and HIV risk, and a causal link has not been established. Furthermore, only limited data are available on other progestin-based HCs. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial was the first large randomized controlled clinical trial comparing the HIV acquisition risk of women receiving DMPA, the levonorgestrel (LNG) implant, or the copper intrauterine device (IUD). The data from the ECHO trial did not reveal an increased risk of HIV acquisition for women on any of these three contraceptives (<xref rid="B3" ref-type="bibr">3</xref>). While reassuring, this study was powered to detect a 50% increase in risk between methods; thus smaller, and notably less clinically significant, differences in risk may not have been detected. Even in the absence of clinical impact, it is still important to have an in-depth understanding of the effects of hormone treatments on the female genital tract (FGT).</p>
              <p>Multiple biological mechanisms have been proposed to account for the potential association between progestin contraceptive use and increased HIV risk (<xref rid="B4" ref-type="bibr">4</xref>). Gonadal hormones are known to be immunomodulatory (<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">–</xref><xref rid="B9" ref-type="bibr">9</xref>). Credence to the scientific premise of immune changes with hormone concentrations is highlighted by pregnancy and menopause (<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">–</xref><xref rid="B12" ref-type="bibr">12</xref>). High levels of estrogen and progesterone during pregnancy are associated with a shift from a T<sub>H</sub>1 to a T<sub>H</sub>2 dominant immune profile, dampening the proinflammatory pathways, and increasing susceptibility to certain disease conditions such as influenza and malaria (<xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">–</xref><xref rid="B17" ref-type="bibr">17</xref>). The active component of DMPA, medroxyprogesterone acetate (MPA), binds more strongly than other progestins to glucocorticoid receptors expressed by immune cells (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), and MPA may therefore alter local and/or systemic immune responses. Despite the suppression of key regulators of cellular and humoral immunity against HIV, MPA has also been demonstrated in some studies to increase the frequency of activated CD4<sup>+</sup> T cells in the FGT, thereby enhancing potential target cell numbers for HIV (<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">–</xref><xref rid="B22" ref-type="bibr">22</xref>).</p>
              <p>In recent years, the interplay between the vaginal microbiota and local immune factors has become increasingly evident as an important factor in the regulation of local and systemic immune function (<xref rid="B23" ref-type="bibr">23</xref><xref rid="B24" ref-type="bibr">–</xref><xref rid="B25" ref-type="bibr">25</xref>). Molecular studies have shown that there are different types of cervicovaginal microbiota that differ in bacterial species composition and dynamics. At least five major types of vaginal microbiota or community state types (CSTs) have been identified (<xref rid="B26" ref-type="bibr">26</xref>). Four of these CSTs are dominated by one of four species of <italic toggle="yes">Lactobacillus</italic> (CST I, <named-content content-type="genus-species">L. crispatus</named-content>; CST II, <named-content content-type="genus-species">L. gasseri</named-content>; CST III, <italic toggle="yes">L. iners</italic>; CST V, <named-content content-type="genus-species">L. jensenii</named-content>), while CST IV is characterized by a paucity of <italic toggle="yes">Lactobacillus</italic> bacteria and the presence of a diverse array of strict and facultative anaerobes, such as <named-content content-type="genus-species">Gardnerella vaginalis</named-content>, <named-content content-type="genus-species">Atopobium vaginae</named-content>, and <italic toggle="yes">Prevotella</italic> spp., among others (<xref rid="B26" ref-type="bibr">26</xref>). CSTs dominated by <italic toggle="yes">Lactobacillus</italic> species are characterized by a low vaginal pH (&lt;4.5), which is driven by lactic acid produced by the <italic toggle="yes">Lactobacillus</italic> spp. present (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). These original CST classifications were established in predominantly White and/or non-Hispanic healthy women of Western Europe and high-income countries, where about 75% of these women harbor <italic toggle="yes">Lactobacillus</italic>-dominated CSTs (<xref rid="B29" ref-type="bibr">29</xref>). Studies evaluating the vaginal microenvironment in sub-Saharan African women have found &lt;50% <italic toggle="yes">Lactobacillus</italic> dominance and a high proportion of women with CST IV cervicovaginal microbiota (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">–</xref><xref rid="B33" ref-type="bibr">33</xref>). Multiple other studies have confirmed differences in the cervicovaginal microbiota of healthy women from different geographic areas and of different races and ethnicities (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>) Hormonal status, menses, sexual practices, vaginal health practices, and pregnancy have been documented to alter the composition of the cervicovaginal microbiota but are likely independent of geographic region, race, and ethnicity (<xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">–</xref><xref rid="B40" ref-type="bibr">40</xref>). The mechanisms by which genetic and environmental factors impact the cervicovaginal microbiota remain unknown. It is critical though to consider such differences in the normal cervicovaginal microbiota of African women in study outcome and data interpretation.</p>
              <p>CST IV, while common in women who are asymptomatic and otherwise healthy, is reminiscent of the syndrome known as bacterial vaginosis (BV), which is also characterized by a lack of <italic toggle="yes">Lactobacillus</italic> spp. and high pH (<xref rid="B41" ref-type="bibr">41</xref><xref rid="B42" ref-type="bibr">–</xref><xref rid="B47" ref-type="bibr">47</xref>). BV can be associated with malodorous vaginal discharge and irritation but is often present in the absence of symptoms. CST IV microbiota evaluated with molecular tools, with or without symptoms, is now referred to as molecular BV (<xref rid="B48" ref-type="bibr">48</xref>). Up to 40% of African women present with symptomatic or asymptomatic BV (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B49" ref-type="bibr">49</xref><xref rid="B50" ref-type="bibr">–</xref><xref rid="B52" ref-type="bibr">52</xref>). While, symptomatic BV has been shown to be a major risk factor for the acquisition of HIV and other sexually transmitted infections (STIs), these risks are also increased in asymptomatic women with BV or CST IV microbiota (<xref rid="B53" ref-type="bibr">53</xref><xref rid="B54" ref-type="bibr">–</xref><xref rid="B57" ref-type="bibr">57</xref>). The enhanced risk of HIV acquisition in these women is due, at least in part, to the more inflammatory milieu that promotes recruitment of HIV target cells to the vaginal mucosa (<xref rid="B58" ref-type="bibr">58</xref>). In contrast, when the cervicovaginal microbiota is dominated by <italic toggle="yes">Lactobacillus</italic> species, particularly <named-content content-type="genus-species">L. crispatus</named-content>, HIV incidence is decreased (<xref rid="B24" ref-type="bibr">24</xref>) compared to that in women with CST IV cervicovaginal microbiota (<xref rid="B24" ref-type="bibr">24</xref>).</p>
              <p>The effect of hormonal contraceptives (HCs) on BV or molecular BV remains controversial. Some studies implied that increased HIV susceptibility in women with HC is related to a decrease in <italic toggle="yes">Lactobaccillus</italic> species and an increase in CST IV cervicovaginal microbiota (<xref rid="B59" ref-type="bibr">59</xref><xref rid="B60" ref-type="bibr">–</xref><xref rid="B62" ref-type="bibr">62</xref>). Interestingly, other studies have suggested that specific HC methods might be protective against BV (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>). A meta-analysis including 55 studies reported a ~25% reduction in both incident and prevalent BV (symptomatic and asymptomatic combined) with HC use (progestin only or combined estrogen-progestin methods) (<xref rid="B65" ref-type="bibr">65</xref>). Many of these studies are limited by their observational, and often cross-sectional study, designs as well as the use of different diagnoses of BV using clinical signs and symptoms (Amsel criteria) (<xref rid="B41" ref-type="bibr">41</xref>) or a Gram stain often used in research settings (Nugent score) (<xref rid="B42" ref-type="bibr">42</xref>). Molecular methods relying on the amplification and sequencing of the 16S rRNA gene can describe the bacterial composition and relative abundance with genus and species resolution, thus affording the opportunity to study the effect of contraceptives on specific members of the microbiota. Few studies have applied these molecular methods to evaluate the impact of contraceptives on the vaginal microenvironment, especially using comparative prospective study designs.</p>
              <p>Given these gaps in our understanding of a critical public, and specifically maternal, health issue, we aimed to clarify the effects of DMPA and the levonorgestrel (LNG) implant on cervicovaginal inflammation and microbiota. We leveraged a previously conducted randomized clinical trial of DMPA and LNG implants (<xref rid="B66" ref-type="bibr">66</xref>) in Malawi to compare the vaginal microbiota compositions and immune mediator concentrations in the genital tract before and after contraceptive initiation among women living with HIV (WHIV) and women without HIV.</p>
            </sec>
            <sec sec-type="results" id="s2">
              <title>RESULTS</title>
              <sec id="s2-1">
                <title>Characteristics of study participants.</title>
                <p>Between May 2014 and April 2015, we randomized 24 women without HIV (12 to DMPA and 12 to the LNG implant) (<xref rid="tab1" ref-type="table">Table 1</xref> and <xref rid="fig1" ref-type="fig">Fig. 1</xref>) and 73 WHIV (37 to DMPA and 36 to the LNG implant) (<xref rid="tab2" ref-type="table">Table 2</xref>). Among women without HIV, the median ages were 27 years among DMPA users and 26 years among implant users. A quarter (<italic toggle="yes">n</italic> = 3) of implant users, but no DMPA users, had a genital tract infection diagnosed during the study.</p>
                <fig position="float" id="fig1">
                  <label>FIG 1</label>
                  <caption>
                    <p>Study overview. Shown is an overview of the enrollment steps for the randomized trial to test the effect of DMPA versus LNG implant on local immune markers and the vaginal microbiome in women without HIV and in WHIV.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f001" position="anchor"/>
                </fig>
                <table-wrap position="float" id="tab1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Baseline characteristics of women without HIV randomized to DMPA or LNG implant</p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="2" colspan="1">Characteristic at study enrollment</th>
                          <th colspan="2" rowspan="1">Result for:<hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">DMPA</th>
                          <th rowspan="1" colspan="1">LNG implant</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Women without HIV (<italic toggle="yes">n</italic> = 24), no.</td>
                          <td rowspan="1" colspan="1">12</td>
                          <td rowspan="1" colspan="1">12</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median age, yr (IQR)<xref rid="ngtab1-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td>
                          <td rowspan="1" colspan="1">26.5 (22.5–34.0)</td>
                          <td rowspan="1" colspan="1">26.0 (23.0–30.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median wt, kg (IQR)</td>
                          <td rowspan="1" colspan="1">53.0 (49.3–57.8)</td>
                          <td rowspan="1" colspan="1">53.5 (49.1–58.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Marital status, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Married</td>
                          <td rowspan="1" colspan="1">11 (91.7)</td>
                          <td rowspan="1" colspan="1">10 (83.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Separated/divorced/widowed/never married</td>
                          <td rowspan="1" colspan="1">1 (8.3)</td>
                          <td rowspan="1" colspan="1">2 (16.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Education, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Primary school or less</td>
                          <td rowspan="1" colspan="1">4 (33.3)</td>
                          <td rowspan="1" colspan="1">7 (58.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At least secondary school</td>
                          <td rowspan="1" colspan="1">8 (66.7)</td>
                          <td rowspan="1" colspan="1">5 (41.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median no. of living children, (IQR)</td>
                          <td rowspan="1" colspan="1">2.5 (1.5–4.0)</td>
                          <td rowspan="1" colspan="1">2.0 (2.0–3.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Past use of hormonal contraception, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">9 (75.0)</td>
                          <td rowspan="1" colspan="1">9 (75.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">3 (25.0)</td>
                          <td rowspan="1" colspan="1">3 (25.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Having sexual partners in past 3 mo, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">12 (100.0)</td>
                          <td rowspan="1" colspan="1">7 (58.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">5 (41.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Prostate-specific antigen at any study visit, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Positive</td>
                          <td rowspan="1" colspan="1">11 (91.7.6)</td>
                          <td rowspan="1" colspan="1">9 (75.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Negative</td>
                          <td rowspan="1" colspan="1">1 (8.3)</td>
                          <td rowspan="1" colspan="1">3 (25.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Genital tract infection at any study visit, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">3 (25.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">12 (100.0)</td>
                          <td rowspan="1" colspan="1">9 (75.0)</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="msphere.00585-22_tab1" position="anchor"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab1-1">
                      <label>a</label>
                      <p>IQR, interquartile range.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="tab2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Baseline characteristics of women with HIV randomized to DMPA or LNG implant</p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="2" colspan="1">Characteristic at study enrollment<xref rid="ngtab2-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                          <th colspan="2" rowspan="1">Result for:<hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">DMPA</th>
                          <th rowspan="1" colspan="1">LNG implant</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Women with HIV (<italic toggle="yes">n</italic> = 73), no.</td>
                          <td rowspan="1" colspan="1"> 37</td>
                          <td rowspan="1" colspan="1">36</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median age, yr (IQR)<xref rid="ngtab2-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td>
                          <td rowspan="1" colspan="1">36.0 (30.0–39.0)</td>
                          <td rowspan="1" colspan="1">34.0 (29.5–38.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median wt, kg (IQR)</td>
                          <td rowspan="1" colspan="1">53.5 (49.8–57.8)</td>
                          <td rowspan="1" colspan="1">56.6 (52.5–63.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Marital status, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Married</td>
                          <td rowspan="1" colspan="1">24 (64.9)</td>
                          <td rowspan="1" colspan="1">23 (63.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Separated/divorced/widowed/never married</td>
                          <td rowspan="1" colspan="1">13 (35.1)</td>
                          <td rowspan="1" colspan="1">13 (36.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Education, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Primary school or less</td>
                          <td rowspan="1" colspan="1">23 (62.2)</td>
                          <td rowspan="1" colspan="1">22 (61.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At least secondary school</td>
                          <td rowspan="1" colspan="1">14 (37.8)</td>
                          <td rowspan="1" colspan="1">14 (38.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Median no. of living children (IQR)</td>
                          <td rowspan="1" colspan="1">3 (2–4)</td>
                          <td rowspan="1" colspan="1">2.5 (2–3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Past use of hormonal contraception, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">28 (75.7)</td>
                          <td rowspan="1" colspan="1">27 (75.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">9 (24.3)</td>
                          <td rowspan="1" colspan="1">9 (25.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Having sexual partners in past 3 mo, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">24 (64.9)</td>
                          <td rowspan="1" colspan="1">23 (63.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">13 (35.1)</td>
                          <td rowspan="1" colspan="1">13 (36.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Prostate-specific antigen at any study visit, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Positive</td>
                          <td rowspan="1" colspan="1">18 (48.6)</td>
                          <td rowspan="1" colspan="1">17 (47.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Negative</td>
                          <td rowspan="1" colspan="1">19 (51.4)</td>
                          <td rowspan="1" colspan="1">19 (52.8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Genital tract infection at any study visit, no. (%)<xref rid="ngtab2-2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1"> 17 (48.6)</td>
                          <td rowspan="1" colspan="1">14 (38.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">20 (54.1)</td>
                          <td rowspan="1" colspan="1">22 (61.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Diagnosed with HIV, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;1 yr ago</td>
                          <td rowspan="1" colspan="1">3 (8.1)</td>
                          <td rowspan="1" colspan="1">5 (13.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 1–5 yr ago</td>
                          <td rowspan="1" colspan="1">23 (62.2)</td>
                          <td rowspan="1" colspan="1">16 (44.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &gt;5 yr ago</td>
                          <td rowspan="1" colspan="1">11 (29.7)</td>
                          <td rowspan="1" colspan="1">15 (41.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Currently on ART, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Yes</td>
                          <td rowspan="1" colspan="1">33 (89.2)</td>
                          <td rowspan="1" colspan="1">35 (97.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No</td>
                          <td rowspan="1" colspan="1">4 (10.8)</td>
                          <td rowspan="1" colspan="1">1 (2.8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">ART start, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;1 yr ago</td>
                          <td rowspan="1" colspan="1">4 (12.1)</td>
                          <td rowspan="1" colspan="1">6 (17.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 1–5 yr ago</td>
                          <td rowspan="1" colspan="1">22 (66.7)</td>
                          <td rowspan="1" colspan="1">18 (51.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &gt;5 yr ago</td>
                          <td rowspan="1" colspan="1">7 (21.2)</td>
                          <td rowspan="1" colspan="1">11 (31.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Plasma HIV viremia, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Detectable at any study visit</td>
                          <td rowspan="1" colspan="1">11 (29.6)</td>
                          <td rowspan="1" colspan="1">15 (41.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Below LOD at all study visits</td>
                          <td rowspan="1" colspan="1">26 (70.4)</td>
                          <td rowspan="1" colspan="1">21 (58.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">CVL fluid viremia, no. (%)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Detectable at any study visit</td>
                          <td rowspan="1" colspan="1">10 (27.0)</td>
                          <td rowspan="1" colspan="1">7 (19.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Below LOD at all study visits</td>
                          <td rowspan="1" colspan="1">27 (73.0)</td>
                          <td rowspan="1" colspan="1">29 (80.6)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">CD4<sup>+</sup> T cell count/μL blood (IQR)</td>
                          <td rowspan="1" colspan="1">426 (278–501)</td>
                          <td rowspan="1" colspan="1">308 (211–449)</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="msphere.00585-22_tab2" position="anchor"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab2-1">
                      <label>a</label>
                      <p>IQR, interquartile range; ART, antiretroviral therapy; CVL, cervicovaginal lavage.</p>
                    </fn>
                    <fn fn-type="other" id="ngtab2-2">
                      <label>b</label>
                      <p>Infections included <named-content content-type="genus-species">Chlamydia trachomatis</named-content>, <named-content content-type="genus-species">Neisseria gonorrhoeae</named-content>, bacterial vaginosis, yeast infection, and <named-content content-type="genus-species">Trichomonas vaginalis</named-content>. Note that some women had multiple infections with different pathogens.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Among WHIV, the median ages were 36 and 34 years and CD4<sup>+</sup> T cell counts were 426 cells/μL and 308 cells/μL for DMPA and implant users, respectively (<xref rid="tab2" ref-type="table">Table 2</xref>). Most WHIV (<italic toggle="yes">n</italic> = 68) were on antiretroviral therapy (ART) at enrollment (89% and 97% in the DMPA and implant arms, respectively). Of the 33 DMPA users on ART, 28 (85%) were on efavirenz-containing therapy, and 15% (<italic toggle="yes">n</italic> = 5) were on nevirapine-containing therapy. Of the 35 LNG implant users on ART, 30 (86%) were on efavirenz-containing therapy, 3 (8%) were on nevirapine-containing therapy, and 2 (6%) were on atazanavir-based therapy. During the study, genital tract infections (mostly trichomoniasis) (<xref rid="tab2" ref-type="table">Table 2</xref> and see <xref rid="tabS1" ref-type="supplementary-material">Table S1</xref> in the supplemental material) were diagnosed in 49% (<italic toggle="yes">n</italic> = 17) and 39% (<italic toggle="yes">n</italic> = 14) of WHIV in the DMPA and implant arms, respectively, and these women received the Malawi standard-of-care treatment. Treatment reduced the incidence of detectable infections in the female genital tract, but as visit intervals increased (and medical observations and treatment access decreased), the infection appeared to increase again in WHIV (<xref rid="tabS1" ref-type="supplementary-material">Table S1</xref>).</p>
                <supplementary-material position="float" id="tabS1" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.6</object-id>
                  <label>TABLE S1</label>
                  <p>Genital tract infections of study participants. Download <inline-supplementary-material id="tS1" xlink:href="msphere.00585-22-s0001.pdf" content-type="local-data">Table S1, PDF file, 0.01 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <p>Plasma HIV viremia was detectable at any study visit in 30% (<italic toggle="yes">n</italic> = 11) and 42% (<italic toggle="yes">n</italic> = 15) of the DMPA and implant arm participants, respectively. Cervicovaginal lavage (CVL) fluid HIV RNA was detectable at any study visit in 27% (<italic toggle="yes">n</italic> = 10) and 19% (<italic toggle="yes">n</italic> = 7) of WHIV in the DMPA and LNG implant arms, respectively, but among these women, few women had detectable CVL HIV RNA at multiple study visits (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). The ranges of plasma HIV viral load during the study were 42 to 223,582 copies/mL for DMPA users and 41 to 86,766 copies/mL for LNG implant users, whereas the cervicovaginal HIV viral load at any visit ranged from 40 to 3,756 copies/mL for DMPA users and 40 to 1,544 copies/mL for LNG implant users (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>).</p>
              </sec>
              <sec id="s2-2">
                <title>Impact of contraception on immune mediators in the vaginal tract.</title>
                <p>Prior to HC initiation, at visit 2, WHIV exhibited higher CVL concentrations of interleukin-1α (IL-1α) (<italic toggle="yes">P</italic> = 0.0369), C-X-C motif chemokine-10 (CXCL-10) (<italic toggle="yes">P</italic> = 0.0167), and beta defensin 3 (BD3) (<italic toggle="yes">P</italic> = 0.0200) than women without HIV (<xref rid="fig2" ref-type="fig">Fig. 2</xref>), but these differences were no longer significantly different after adjusting for multiple comparisons.</p>
                <fig position="float" id="fig2">
                  <label>FIG 2</label>
                  <caption>
                    <p>Vaginal cytokine milieu prior to contraceptive start. Shown are the median concentrations ± 95% confidence interval (CI) of various immune markers in cervicovaginal lavage samples of women without HIV (gray triangles) in comparison to WHIV (black triangles) at study visit 2. Statistical comparisons were performed by Mann-Whitney test.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f002" position="anchor"/>
                </fig>
                <p>When comparing the levels of each immune mediator at visit 4 (day 3) to visit 2 to assess acute changes with HC use, and when comparing visit 7 to visit 2 to determine a potential long-term effect of HC use, few changes were notable. WHIV on DMPA experienced a decrease in vaginal gamma interferon (IFN-γ) and BD-3 levels and an increase in IL-1α at visit 4 compared to visit 2 (<xref rid="fig3" ref-type="fig">Fig. 3A</xref>), but these changes were transient and no longer detectable at visit 7 (<xref rid="fig3" ref-type="fig">Fig. 3B</xref>). At visit 7, median IL-8 concentrations were lower in WHIV on DMPA than at baseline. However, none of these changes in cytokine levels were statistically significant when correcting for multiple comparisons. These results also imply that any infections other than HIV in the female genital tract during the study period (see <xref rid="tabS1" ref-type="supplementary-material">Table S1</xref>) did not further impact the vaginal immune milieu beyond that of the HIV-associated immune activation that was noted at visit 2 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).</p>
                <fig position="float" id="fig3">
                  <label>FIG 3</label>
                  <caption>
                    <p>Changes in immune markers of WHIV after contraceptive initiation. Shown are the median concentrations ± 95% CI of various immune markers in CVL samples of WHIV assigned to DMPA (top panels) or the LNG implant (bottom panels) at study visit 4 (gray triangles, left panels) and visit 7 (right panels, gray triangles) compared to visit 2 (black triangles). Statistical comparisons were performed by paired Wilcoxon rank test.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f003" position="anchor"/>
                </fig>
                <p>LNG users among WHIV did not experience any changes in vaginal immune mediators (<xref rid="fig3" ref-type="fig">Fig. 3C</xref> and <xref rid="fig3" ref-type="fig">D</xref>). In women without HIV, independent of the type of contraceptive, no differences were observed in the vaginal immune milieu (<xref rid="fig4" ref-type="fig">Fig. 4</xref>).</p>
                <fig position="float" id="fig4">
                  <label>FIG 4</label>
                  <caption>
                    <p>Changes in immune markers in women without HIV after contraceptive initiation. Shown are the median concentrations ± 95% CI of various immune markers in CVL samples of women without HIV assigned to the DMPA (top panels) or the LNG implant (bottom panels) group at study visit 4 (gray circles, left panels) and visit 7 (right panels, gray circles) compared to visit 2 (white circles).</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f004" position="anchor"/>
                </fig>
                <p>When comparing the concentrations of each immune marker at specific time points (visits 2, 4, and 7) between DMPA and LNG implant users among women without HIV (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>) and among WHIV (<xref rid="fig5" ref-type="fig">Fig. 5B</xref>), there were no differences in immune mediator concentrations noted, with the exception of slightly reduced BD3 levels at visit 7 in WHIV on LNG versus DMPA. In addition, these comparisons were repeated without stratifying by HIV status, with similar findings of no changes in overall cytokine measurements between contraceptive arms or with time within each arm with contraceptive use (data not shown).</p>
                <fig position="float" id="fig5">
                  <label>FIG 5</label>
                  <caption>
                    <p>Comparative analysis of changes in vaginal immune markers dependent on the type of contraceptive method. The median concentrations ± 95% CI of various immune markers in CVL samples of women without HIV (A) or WHIV (B) were compared at visit 2 (prior to contraceptive use), visit 4 (day 3 post-contraceptive start), and visit 7 (6 months post-contraceptive start) between women assigned to the DMPA (white circles) or the LNG implant (gray circles) group.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f005" position="anchor"/>
                </fig>
              </sec>
              <sec id="s2-3">
                <title>Vaginal microbiota characteristics at baseline prior to HC initiation (visit 2).</title>
                <p>Data were available for 20 of 24 (83.3%) women without HIV and for 62 of 72 (84.9%) WHIV. Among the 20 women without HIV, <named-content content-type="genus-species">L. crispatus</named-content>-dominated vaginal microbiota (CST I) was found in 4 women (20.0%), and 1 woman had a microbiome classified as CST II (<named-content content-type="genus-species">L. gasseri</named-content> dominated). About equal numbers of women without HIV had a vaginal microbiota that was characteristic of CST III (<italic toggle="yes">L. iners</italic> dominated; <italic toggle="yes">n</italic> = 7; 35%) or CST IV (<italic toggle="yes">n</italic> = 8; 40%). Among WHIV, consistent with the more inflammatory vaginal milieu observed at baseline, only 8.1% (<italic toggle="yes">n</italic> = 5) of women had a CST I vaginal microbiota. Similar to women without HIV, the vaginal microbiota composition in about one-third of WHIV (32.3%; <italic toggle="yes">n</italic> = 20) was classified as CST III, dominated by <italic toggle="yes">L. iners</italic> (CST III). CST IV was characterized by no or a low level of <italic toggle="yes">Lactobacillus</italic>, and an array of strict and facultative anaerobes, including <italic toggle="yes">G. vaginalis</italic>, was the most prevalent CST in WHIV (59.7%; <italic toggle="yes">n</italic> = 37) (<xref rid="tab3" ref-type="table">Table 3</xref>). Thus, comparing the number of women with CST I, CST II, CST III, or CST IV at baseline (visit 2), the vaginal microbiota of women with HIV was not distinct from that of women without HIV (<italic toggle="yes">P</italic> = 0.095) by Fisher’s exact test.</p>
                <table-wrap position="float" id="tab3">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Microbiome classification of women prior to contraceptive use (visit 2)</p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="3" colspan="1">CST<xref rid="ngtab3-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                          <th colspan="9" rowspan="1">No. (%) of women with CST shown<xref rid="ngtab3-2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref><hr/></th>
                        </tr>
                        <tr>
                          <th colspan="3" rowspan="1">All women (<italic toggle="yes">n</italic> = 82)<hr/></th>
                          <th colspan="3" rowspan="1">Women without HIV (<italic toggle="yes">n</italic> = 20)<hr/></th>
                          <th colspan="3" rowspan="1">WHIV (<italic toggle="yes">n</italic> = 62)<hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">Total</th>
                          <th rowspan="1" colspan="1">DMPA</th>
                          <th rowspan="1" colspan="1">LNG implant</th>
                          <th rowspan="1" colspan="1">Total</th>
                          <th rowspan="1" colspan="1">DMPA</th>
                          <th rowspan="1" colspan="1">LNG implant</th>
                          <th rowspan="1" colspan="1">Total</th>
                          <th rowspan="1" colspan="1">DMPA</th>
                          <th rowspan="1" colspan="1">LNG implant</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">I</td>
                          <td rowspan="1" colspan="1">9 (11.0)</td>
                          <td rowspan="1" colspan="1">4 (9.3)</td>
                          <td rowspan="1" colspan="1">5 (12.8)</td>
                          <td rowspan="1" colspan="1">4 (20.0)</td>
                          <td rowspan="1" colspan="1">1 (9.1)</td>
                          <td rowspan="1" colspan="1">3 (33.3)</td>
                          <td rowspan="1" colspan="1">5 (8.1)</td>
                          <td rowspan="1" colspan="1">3 (9.4)</td>
                          <td rowspan="1" colspan="1">2 (6.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">II</td>
                          <td rowspan="1" colspan="1">1 (1.2)</td>
                          <td rowspan="1" colspan="1">1 (2.3)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">1 (5.0)</td>
                          <td rowspan="1" colspan="1">1 (9.1)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">III</td>
                          <td rowspan="1" colspan="1">27 (32.9)</td>
                          <td rowspan="1" colspan="1">11 (25.6)</td>
                          <td rowspan="1" colspan="1">16 (41.0)</td>
                          <td rowspan="1" colspan="1">7 (35.0)</td>
                          <td rowspan="1" colspan="1">4 (36.4)</td>
                          <td rowspan="1" colspan="1">3 (33.3)</td>
                          <td rowspan="1" colspan="1">20 (32.2)</td>
                          <td rowspan="1" colspan="1">7 (21.9)</td>
                          <td rowspan="1" colspan="1">13 (43.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">IV</td>
                          <td rowspan="1" colspan="1">45 (54.9)</td>
                          <td rowspan="1" colspan="1">27 (62.8)</td>
                          <td rowspan="1" colspan="1">18 (46.2)</td>
                          <td rowspan="1" colspan="1">8 (40.0)</td>
                          <td rowspan="1" colspan="1">5 (45.4)</td>
                          <td rowspan="1" colspan="1">3 (33.3)</td>
                          <td rowspan="1" colspan="1">37 (59.7)</td>
                          <td rowspan="1" colspan="1">22 (68.8)</td>
                          <td rowspan="1" colspan="1">15 (46.9)</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="msphere.00585-22_tab3" position="anchor"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab3-1">
                      <label>a</label>
                      <p>CST, community state type.</p>
                    </fn>
                    <fn fn-type="other" id="ngtab3-2">
                      <label>b</label>
                      <p>The DMPA and LNG implant results represent the number (percentage) of women randomly assigned to a specific hormonal contraceptive at visit 3.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The vaginal microbiota composition was unknown at visit 3 when women were randomly assigned to DMPA or LNG implant. Among the women without HIV who initiated DMPA (<italic toggle="yes">n</italic> = 11), women with a CST I (<italic toggle="yes">n</italic> = 1) or CST II (<italic toggle="yes">n</italic> = 1) vaginal microbiota at visit 2 were less represented than women with CST III (<italic toggle="yes">n</italic> = 4) and CST IV (<italic toggle="yes">n</italic> = 5) (<xref rid="tab3" ref-type="table">Table 3</xref>). In the LNG group of women without HIV, an equal number of women (<italic toggle="yes">n</italic> = 3) had a baseline vaginal microbiota characterized as CST I, CST III, or CST IV (<xref rid="tab3" ref-type="table">Table 3</xref>). Among WHIV, in both the DMPA (<italic toggle="yes">n</italic> = 22 of 32) and LNG (<italic toggle="yes">n</italic> = 15 of 30) groups, the majority of women, about two-thirds (68.8%) and one-half (50%), respectively, had a CST IV-dominated vaginal microbiota. In contrast, less than 10% of WHIV had CST I vaginal microbiota at the time of DMPA or LNG initiation (<xref rid="tab3" ref-type="table">Table 3</xref>).</p>
                <p>Not stratifying by HIV status, women in the DMPA group more frequently presented with CST IV (<italic toggle="yes">n</italic> = 27; 62.8%) and less frequently with CST III (<italic toggle="yes">n</italic> = 11; 25.6%) vaginal microbiota compared to women assigned to LNG (CST IV, <italic toggle="yes">n</italic> = 18, 46.2%; CST III, <italic toggle="yes">n</italic> = 16, 41.0%). Women with CST I-dominated vaginal microbiota were relatively evenly distributed among the DMPA (<italic toggle="yes">n</italic> = 4; 9.3%) and LNG (<italic toggle="yes">n</italic> = 5; 12.8%) groups.</p>
              </sec>
              <sec id="s2-4">
                <title>Effects of hormonal contraceptive use on vaginal microbiota composition.</title>
                <p>After the start of HC use, only minor changes in the CST classifications were observed for each individual stratified by HC method and HIV status (<xref rid="tab4" ref-type="table">Table 4</xref> and <xref rid="fig6" ref-type="fig">Fig. 6</xref>); the most common were transitions between CST III and CST IV, occurring in both directions over time. No correlations were observed between HC type and changes in the abundance of a specific bacterial species. However, the assessment of the change in the median log<sub>10</sub> abundance of all <italic toggle="yes">Lactobacillus</italic> (<italic toggle="yes">Lb</italic>) species combined at visit 7 versus visit 2 [log<sub>10</sub> (<italic toggle="yes">Lb</italic> @ V7/V2)] revealed that the distribution of subjects with smaller compared to larger changes in log<sub>10</sub> (<italic toggle="yes">Lb</italic> @ V7/V2) was different between women who had initiated DMPA or LNG (<xref rid="figS1" ref-type="supplementary-material">Fig. S1</xref>). Thus, the probability that a larger change in log<sub>10</sub> (<italic toggle="yes">Lb</italic> @ V7/V2)—or an increase in overall <italic toggle="yes">Lactobacillus</italic> spp.—after HC initiation occurred was significantly higher for women who were assigned to DMPA (<italic toggle="yes">P</italic> = 0.024), and this effect was more pronounced when the analysis was limited to WHIV (<italic toggle="yes">P</italic> = 0.004). In this context it should be noted that although there was no difference in the median log<sub>10</sub> ratio of the abundance of <named-content content-type="genus-species">Sneathia sanguinegens</named-content> (a bacterial species commonly found in CST IV) at visit 7 versus visit 2 [log<sub>10</sub> (<italic toggle="yes">Ss</italic> @ V7/V2)] between participants in the DMPA and LNG groups, the probability of women experiencing an increase in the abundance of at visit 7 compared to visit 2, was lower (<italic toggle="yes">P</italic> = 0.08) in the DMPA group. WHIV had a significantly higher probability (<italic toggle="yes">P</italic> = 0.0098) of having a change in the median log<sub>10</sub> (<italic toggle="yes">Ss</italic> @ V7/V2) abundance (<xref rid="figS1" ref-type="supplementary-material">Fig. S1</xref>).</p>
                <fig position="float" id="fig6">
                  <label>FIG 6</label>
                  <caption>
                    <p>Changes in the CST classifications for each individual stratified by HC method and HIV status.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f006" position="anchor"/>
                </fig>
                <table-wrap position="float" id="tab4">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Microbiome CST distribution by study visit</p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="2" colspan="1">Visit no.</th>
                          <th colspan="4" rowspan="1">No. (%) of all women<xref rid="ngtab4-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref><hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">CST I</th>
                          <th rowspan="1" colspan="1">CST II</th>
                          <th rowspan="1" colspan="1">CST III</th>
                          <th rowspan="1" colspan="1">CST IV</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">2</td>
                          <td rowspan="1" colspan="1">9 (11.0)</td>
                          <td rowspan="1" colspan="1">1 (1.2)</td>
                          <td rowspan="1" colspan="1">27 (32.9)</td>
                          <td rowspan="1" colspan="1">45 (54.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">4</td>
                          <td rowspan="1" colspan="1">8 (9.0)</td>
                          <td rowspan="1" colspan="1">0 (0.0)</td>
                          <td rowspan="1" colspan="1">30 (33.7)</td>
                          <td rowspan="1" colspan="1">51 (57.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">5</td>
                          <td rowspan="1" colspan="1">8 (9.3)</td>
                          <td rowspan="1" colspan="1">1 (1.2)</td>
                          <td rowspan="1" colspan="1">30 (34.9)</td>
                          <td rowspan="1" colspan="1">47 (54.6)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">6</td>
                          <td rowspan="1" colspan="1">11 (13.1)</td>
                          <td rowspan="1" colspan="1">1 (1.2)</td>
                          <td rowspan="1" colspan="1">25 (29.8)</td>
                          <td rowspan="1" colspan="1">47 (56.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">7</td>
                          <td rowspan="1" colspan="1">7 (8.6)</td>
                          <td rowspan="1" colspan="1">3 (3.2)</td>
                          <td rowspan="1" colspan="1">31 (33.7)</td>
                          <td rowspan="1" colspan="1">51 (55.4)</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="msphere.00585-22_tab4" position="anchor"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab4-1">
                      <label>a</label>
                      <p>Results are shown as the number (percentage) of all women independent of HIV status and HC use. Note that the total numbers of women with samples at individual visits differed (range, <italic toggle="yes">n</italic> = 82 to 92).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <supplementary-material position="float" id="figS1" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.1</object-id>
                  <label>FIG S1</label>
                  <p>Changes in the abundance of distinct bacterial taxa in relation to contraceptive use. (A) Graphed is the log<sub>10</sub> change in the relative abundance of (from left to right) lactobacilli <italic toggle="yes">L. iners</italic> and <named-content content-type="genus-species">L. crispatus</named-content> or <named-content content-type="genus-species">Sneathia sanguinegens</named-content> at visit 7 compared to visit 2 (<italic toggle="yes">y</italic> axis) in women who received the LNG implant or DMPA. Each dot represents an individual woman. (B) Graphed is the log<sub>10</sub> change in the relative abundance of (from left to right) lactobacilli, <italic toggle="yes">L. iners</italic>, <named-content content-type="genus-species">L. crispatus</named-content>, or <italic toggle="yes">S. sanguinegens</italic> at visit 7 compared to visit 2 (<italic toggle="yes">x</italic> axis) in relation to the likelihood that the woman has received DMPA treatment. The likelihood that an increase in overall <italic toggle="yes">Lactobacillus</italic> spp. after HC initiation occurred was significantly higher for women who were assigned to DMPA (<italic toggle="yes">P</italic> = 0.04). In contrast, the likelihood of women to experience an increase in the abundance of <named-content content-type="genus-species">Sneathia sanguinegens</named-content>, a bacterial species commonly found in CST IV, at visit 7 compared to visit 2 was lower (<italic toggle="yes">P</italic> = 0.0098) in the DMPA group. Download <inline-supplementary-material id="fS1" xlink:href="msphere.00585-22-s0002.eps" content-type="local-data">FIG S1, EPS file, 1.8 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <p>Shannon diversity (<xref rid="figS2" ref-type="supplementary-material">Fig. S2</xref>) and total bacterial load (<xref rid="figS3" ref-type="supplementary-material">Fig. S3</xref>) did not differ significantly between the DMPA and LNG implant groups together and within group medians after the start of HC use.</p>
                <supplementary-material position="float" id="figS2" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.2</object-id>
                  <label>FIG S2</label>
                  <p>Heat map of Shannon diversity prior and post-contraceptive use. The <italic toggle="yes">x</italic> axis indicates the visit number, the left <italic toggle="yes">y</italic> axis shows bars for women assigned to DMPA (blue) or LNG implant (orange) group and dependent on HIV status. The right <italic toggle="yes">y</italic> axis lists the individual women. The Shannon diversity for each woman at each visit is represented on a color heat scale ranging from lowest (yellow) to highest (red). Download <inline-supplementary-material id="fS2" xlink:href="msphere.00585-22-s0003.eps" content-type="local-data">FIG S2, EPS file, 1.8 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material position="float" id="figS3" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.3</object-id>
                  <label>FIG S3</label>
                  <p>Heat map of bacterial load prior and post-contraceptive use. The <italic toggle="yes">x</italic> axis indicates the visit number, and the left <italic toggle="yes">y</italic> axis shows bars for women assigned to DMPA (blue) or LNG implant (orange) and dependent on HIV status. The right <italic toggle="yes">y</italic> axis lists the individual women. The bacterial load for each woman at each visit is represented on a color heat scale ranging from 1E10 in yellow to 5E10 in red. Download <inline-supplementary-material id="fS3" xlink:href="msphere.00585-22-s0004.eps" content-type="local-data">FIG S3, EPS file, 1.9 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
              <sec id="s2-5">
                <title>Potential interactions between HIV status, local immune milieu, vaginal microbiota, and contraceptive use.</title>
                <p>Despite the lack of major changes in the vaginal immune milieu or microbiota after HC initiation, there were some notable signals of interactions between HIV status, vaginal immune milieu, vaginal microbiota, and HC use. Consistent with the fact that bacterial species characteristic for CST IV promote a more inflammatory milieu, higher levels of some inflammatory cytokines in WHIV compared to women without HIV prior to HC use at visit 2 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) were only detectable in comparative analyses of women with CST I or CST III vaginal microbiota (<xref rid="figS4" ref-type="supplementary-material">Fig. S4</xref>). Post-HC initiation, we did not observe any changes in immune markers based on HC method at visits 4 and 7, when we stratified women without HIV or WHIV by CST (<xref rid="figS5" ref-type="supplementary-material">Fig. S5</xref> and data not shown). There was, however, a change in the median log<sub>10</sub> ratio of IL-12p40 to IL-10 concentrations at visit 7 compared to visit 2 (−0.137) across all women after initiation of HC use with <italic toggle="yes">P</italic> = 0.004. The change in the log<sub>10</sub> (IL-12/IL-10 @ V7/V2) after HC initiation was strongest in WHIV (median difference, −0.1550; <italic toggle="yes">P</italic> = 0.0011) and appeared to be driven primarily by women in the DMPA group (median difference, −0.2110; <italic toggle="yes">P</italic> = 0.0017) compared to the LNG group (median difference, −0.0679; <italic toggle="yes">P</italic> = 0.2830), although there was no significant difference (<italic toggle="yes">P</italic> = 0.0809) between women who had initiated DMPA versus those who had initiated LNG. Further analysis demonstrated that the change in log<sub>10</sub> (IL-12/IL-10 @ V7/V2) was at least partially dependent on the CST classification at baseline (<xref rid="tab5" ref-type="table">Table 5</xref>). Thus, women with CST IV at visit 2 were more likely to have a significant change in the median ratio of log<sub>10</sub> (IL-12/IL-10 @ V7/V2) than women with vaginal microbiota classified as CST I or CST III at baseline (<xref rid="tab5" ref-type="table">Table 5</xref>). A similar effect was observed for the change in the median log<sub>10</sub> IFN-γ/IL-10 ratio at visit 7 compared to visit 2 (<xref rid="tab5" ref-type="table">Table 5</xref>). When considering single cytokines, women with vaginal microbiota classified as CST IV at visit 2 had a decrease in the median concentrations of log<sub>10</sub> (IL-12 @ V7/V2) after HC initiation. Across all women, the probability of a change in the median concentration of log<sub>10</sub> (IL-12 @ V7/V2) was inversely related to the likelihood that a woman had received DMPA (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). There was also an inverse relationship between the change of the median concentration of log<sub>10</sub> (IL-12 @ V7/V2) and the median log<sub>10</sub> abundance of <italic toggle="yes">L. iners</italic> at visit 7 compared to visit 2, but only in WHIV (odds ratio [OR], −0.1; <italic toggle="yes">P</italic> = 0.0053) (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). Among WHIV, this significant correlation was not observed for women using the LNG implant (<italic toggle="yes">P</italic> = 0.1350), but it was evident in DMPA-treated women (OR, −0.11; <italic toggle="yes">P</italic> = 0.0224). Such a relationship was not observed for <named-content content-type="genus-species">L. crispatus</named-content> or <named-content content-type="genus-species">L. gasseri</named-content> (data not shown and with no data for <named-content content-type="genus-species">L. jensenii</named-content> due to the limited number of women with <named-content content-type="genus-species">L. jensenii</named-content>). Similar interactions between vaginal microbiota, HC use, and local immune milieu were not observed when other immune markers were considered.</p>
                <fig position="float" id="fig7">
                  <label>FIG 7</label>
                  <caption>
                    <p>Correlation between the DMPA, IL-12p40, and <italic toggle="yes">L. iners</italic> abundance. Panel A shows the negative correlation between the probability of being assigned to DMPA versus the change in IL-12p40 concentration (log<sub>10</sub>) in WHIV. Panel B illustrates the negative correlation between the change in IL-12p40 concentration (log<sub>10</sub>) at visit 7 compared to visit 2 versus the change in relative <italic toggle="yes">L. iners</italic> abundance (log<sub>10</sub>) in WHIV.</p>
                  </caption>
                  <graphic xlink:href="msphere.00585-22-f007" position="anchor"/>
                </fig>
                <table-wrap position="float" id="tab5">
                  <label>TABLE 5</label>
                  <caption>
                    <p>Effect of CST classification at visit 2 on vaginal cytokine concentrations after HC initiation</p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="2" colspan="1">Log<sub>10</sub> cytokine change<xref rid="ngtab5-1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th>
                          <th colspan="3" rowspan="1">CST classification at visit 2<hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">CST I</th>
                          <th rowspan="1" colspan="1">CST III</th>
                          <th rowspan="1" colspan="1">CST IV</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Log<sub>10</sub> (IL-12p40/IL-10 @ V7/V2)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Median</td>
                          <td rowspan="1" colspan="1">−0.0336</td>
                          <td rowspan="1" colspan="1">0.0640</td>
                          <td rowspan="1" colspan="1">−0.1660</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> <italic toggle="yes">P</italic> value</td>
                          <td rowspan="1" colspan="1">0.8260</td>
                          <td rowspan="1" colspan="1">0.9780</td>
                          <td rowspan="1" colspan="1">0.0055</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Log<sub>10</sub> (IFN-γ/IL-10 @ V7/V2)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Median</td>
                          <td rowspan="1" colspan="1">−0.0095</td>
                          <td rowspan="1" colspan="1">0.0640</td>
                          <td rowspan="1" colspan="1">−0.1660</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> <italic toggle="yes">P</italic> value</td>
                          <td rowspan="1" colspan="1">0.7900</td>
                          <td rowspan="1" colspan="1">0.9130</td>
                          <td rowspan="1" colspan="1">0.0014</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Log<sub>10</sub> (IL-12p40 @ V7/V2)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Median</td>
                          <td rowspan="1" colspan="1">−0.2680</td>
                          <td rowspan="1" colspan="1">0.1100</td>
                          <td rowspan="1" colspan="1">−0.2860</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> <italic toggle="yes">P</italic> value</td>
                          <td rowspan="1" colspan="1">0.6150</td>
                          <td rowspan="1" colspan="1">0.2050</td>
                          <td rowspan="1" colspan="1">0.0007</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="msphere.00585-22_tab5" position="anchor"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab5-1">
                      <label>a</label>
                      <p>Change in the median log<sub>10</sub> ratio of IL-12p40/IL-10 or IFN-γ/IL-10 concentrations or of IL12-p40 concentrations at visit 7 compared to baseline (visit 2).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <supplementary-material position="float" id="figS4" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.4</object-id>
                  <label>FIG S4</label>
                  <p>Vaginal cytokine milieu prior to contraceptive start based on CST classification. The median concentrations ± 95% confidence intervals of various immune markers in cervicovaginal lavage samples of women without HIV (gray triangles) in comparison to WHIV (black triangles) at study visit 2 based on CST classification are shown. Statistical comparisons were performed by Mann-Whitney test. Download <inline-supplementary-material id="fS4" xlink:href="msphere.00585-22-s0005.eps" content-type="local-data">FIG S4, EPS file, 0.3 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material position="float" id="figS5" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/msphere.00585-22.5</object-id>
                  <label>FIG S5</label>
                  <p>Changes in the vaginal cytokine milieu at visit 4 dependent on HIV and CST status. The median concentrations ± 95% confidence intervals of various immune markers in cervicovaginal lavage samples of women without HIV (top row) and WHIV (bottom graphs) are graphed for visit 4 and compared between women assigned to the DMPA (white circles) or the LNG implant (gray circles) group based on their CST status at visit 2. Download <inline-supplementary-material id="fS5" xlink:href="msphere.00585-22-s0006.eps" content-type="local-data">FIG S5, EPS file, 0.8 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/AuthorWarrantyLicense.v1</ali:license_ref>
                      <license-p>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>DISCUSSION</title>
              <p>Our results of a randomized trial of DMPA or LNG implant among women without HIV and WHIV demonstrate minimal impact of the two different progestin-based hormonal contraceptives on vaginal immune markers or microbiota composition. Furthermore, within each contraceptive arm, we also note no or only minor changes in the composition of the vaginal microbiota at 3 days (visit 4) and 6 months (visit 7) after contraceptive initiation, suggesting that within individuals, there is no altered risk profile. These findings support those from the ECHO trial, add to the reassuring data on DMPA use, and are consistent with recent WHO and CDC medical eligibility criteria (<xref rid="B69" ref-type="bibr">69</xref>).</p>
              <p>We found no long-lasting changes in local immune mediators among women without HIV or WHIV after contraceptive initiation. Although we observed a transient decrease in a few inflammatory cytokines in WHIV at day 3 after DMPA start, none of these changes were significant after Benjamini-Hochberg correction or by month 6. As cytokines do not act in isolation, we had also evaluated changes in the ratio of proinflammatory to anti-inflammatory cytokines (IL-12p40/IL-10 and IFN-γ/IL-10 ratios), and this analysis confirmed that neither DMPA nor LNG impacted the immune milieu in women without HIV or WHIV. We previously reported that some of the WHIV had genital HIV shedding (<xref rid="B67" ref-type="bibr">67</xref>). HC use did not alter the frequency or the amount of HIV shedding in the genital tract (<xref rid="B67" ref-type="bibr">67</xref>), and consistent with the findings of no significant changes in the local immune milieu, we also found no correlation between changes in immune markers and viral shedding.</p>
              <p>In contrast to our results, some previous studies reported that DMPA alters the levels of certain immune markers in the female genital tract. A case-control study from South Africa evaluated 42 CVL markers and found that women without HIV (<italic toggle="yes">n</italic> = 64) using either injectable DMPA or noresthisterone-enanthate had lower IL-12p40, IL-15, monocyte chemotactic protein 1 (MCP-1), eotaxin, macrophage-derived chemokine (MDC), and platelet-derived growth factor-AA (PDGF-AA) concentrations than 64 matched non-HC users at baseline (<xref rid="B70" ref-type="bibr">70</xref>). In a cross-sectional study of Kenyan and South African women without HIV enrolled in the FEM-PrEP trial, DMPA users (<italic toggle="yes">n</italic> = 75) had significantly higher macrophage inflammatory protein 1α (MIP-1α), MIP-1β, IL-6, IL-8, CXCL-10, and RANTES concentrations than the non-HC users (<italic toggle="yes">n</italic> = 99) (<xref rid="B71" ref-type="bibr">71</xref>). Our study could not confirm these findings, but our number of women without HIV assigned to DMPA was relatively small. Differences in study design, population, specimen type, specimen collection timing, and analysis methods may explain and contribute to these different results. We did find, however, an association between the decrease in the median log<sub>10</sub> (IL-12/IL-10 @ V7/V2) ratio in WHIV when these WHIV were classified with a CST IV-dominated vaginal microbiota at baseline and randomized to initiate DMPA. A decrease in the median ratios of IL-12p40 or IFN-γ to IL-10 from V7/V2 could be due to an increase in IL-10 levels, a decrease in IL-12p40, or both, but the relative increase in IL-10 exceeded the relative decrease of IL-12p40. Biologically that translates into a less inflammatory milieu. This observation was most prominent in HIV women of the DMPA group, but it was only significant when these women presented with CST IV at baseline, implying that a potentially immunosuppressive effect of DMPA would only have a biological impact in specific subpopulations. These findings underline the complexity of the interaction between HC, local immune milieu, and cervicovaginal microbiota. The caveat of our study is the rather small sample size when we focused our analysis on a subgroup of women depending on HIV status, specific HC use, and CST classification prior to HC initiation.</p>
              <p>Our vaginal microbiota analysis highlights that most women in our Malawian cohort are not <named-content content-type="genus-species">L. crispatus</named-content> dominant. This finding is consistent with several other microbiome studies of sub-Saharan African women (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Although several women in our cohort underwent occasional shifts in the microbiota composition over the course of the study, the changes were generally transient, with the vast majority maintaining a CST III or CST IV state of their vaginal microbiota. Thus, overall, the contraceptive exposure did not lead to any consistent and significant changes. DMPA use resulted in a slight decrease in bacterial load, suggesting that qualitative and quantitative changes in microbiota composition need to be assessed to determine the impact of contraceptives on the vaginal microbiota.</p>
              <p>In addition, underlying conditions, such as BV or other infections in the FGT, may impact the outcome of contraceptive use on the local milieu and HIV risk. Indeed, at study entry, the incidence of genital tract infections was higher in WHIV than in women without HIV. A recent study of a Zambian discordant cohort found a significant modification of the risk of HIV acquisition with DMPA use when women presented with BV. Women with BV had more than a 6-fold increased risk of HIV in the setting of BV, whereas there was no significantly increased risk in women without BV (<xref rid="B72" ref-type="bibr">72</xref>). Although this finding was not confirmed in some other studies (<xref rid="B73" ref-type="bibr">73</xref>), other studies also demonstrated that vaginal inflammation is attributed to vaginal dysbiosis (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B74" ref-type="bibr">74</xref>). Despite slightly higher numbers of genital tract infections at visit 7 than at visit 4 in WHIV, we did not observe an increase in local inflammation. On the contrary, in WHIV on DMPA, as discussed above, inflammation appeared to lessen during the study course. Our study, however, was underpowered to evaluate the interactions between microbiota composition, local immune milieu, contraceptive use, and HIV status. Larger cohorts are needed to identify these interactions and should be conducted to conclusively define the individual-level risk factors, including specific vaginal microbiota within CST IV, that may influence one’s immunologic response and subsequent risk profile following contraceptive method use.</p>
              <p>Our study has several notable strengths, including its randomized prospective study design and before-after comparisons. We had no loss to follow-up during the 6 months after contraceptive initiation. Our study was limited by its small sample size, particularly in the group of women without HIV. Therefore, we were restricted in the evaluations of distinct stratifications (e.g., CST) and interactions between groups. Additionally, we have limited generalizability as the participants were recruited from a single site; however, Malawi represents a country in the heart of the HIV epidemic, reassuring that our results have translational value.</p>
            </sec>
            <sec sec-type="materials|methods" id="s4">
              <title>MATERIALS AND METHODS</title>
              <sec id="s4-1">
                <title>Study design and enrollment.</title>
                <p>We previously conducted an open-label randomized trial (<ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> registration no. NCT02103660) among women desiring to initiate contraception at the Bwaila Hospital, a large district hospital in Lilongwe, Malawi. The study procedures have been previously described (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Briefly, women interested in study participation underwent informed consent for study screening (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Inclusion criteria included (i) age 18 to 45 years, (ii) known HIV status (as documented during screening), (iii) self-report of at least two regular, monthly cycles (~21 to 35 days) preceding study enrollment, (iv) self-report of not being on hormonal or intrauterine contraception for at least 6 months, (v) at least 6 months postpartum; (vi) interested in initiating DMPA or the LNG implant, (vii) accepting to be randomized to receive either DMPA or the LNG implant, and (viii) willing to wait 4 to 6 weeks after enrollment to receive the contraceptive method (with condom use or abstinence encouraged during this time frame). We excluded women who were pregnant at screening or desiring pregnancy within the next 12 months or who had any medical contraindications to DMPA or LNG implant per the WHO medical eligibility criteria (<xref rid="B75" ref-type="bibr">75</xref>). We also excluded women who were newly diagnosed with HIV at screening but had a known negative HIV test within the past 6 months, because acute HIV infection is associated with high viremia, virus shedding in the FGT, and drastic changes in immune parameters that are not representative of virologic and immune status observed once the viral set point has been reached.</p>
                <p>Eligible women underwent consent for study participation and completed an enrollment interview that included questions on demographic, medical, and reproductive health information. We determined cycle phase by patients’ self-report of the first day of their last menstrual period and defined the follicular phase as within the first 14 days from their last menses, and the luteal phase from day 15 from the onset of their last menses until the start of the next menses. Participants who were determined to be in the follicular phase on the day of enrollment, also completed visit 1 on that day. Otherwise, they were asked to return for visit 1 during the first 14 days of their next anticipated menstrual cycle. At visit 1, an interval history assessment and physical exam were completed. Participants with untreated visible genital ulcers or lesions at the initial pelvic examination were terminated from the study. Visit 2 was scheduled to occur during the luteal phase of the same cycle visit 1. In a few cases, when the participant missed visit 2 in the corresponding visit 1 cycle, visit 2 was rescheduled to the luteal phase of the subsequent cycle. Although cycle length can vary, for consistency, visits 1 and 2 were scheduled assuming a 28-day cycle. We excluded days of menses to avoid blood contamination of cervicovaginal samples.</p>
                <p>At visit 3, within the first 7 days after the start of their next menses, we randomized women to DMPA or the LNG implant using permuted-block randomization schemes that were generated independently for WHIV and women without HIV. Return visits post-HC initiation were scheduled for day 3 (visit 4), day 30 (visit 5), day 90 (visit 6), and day 180 (visit 7). At all visits, patients completed an interval history assessment, a physical and pelvic examination, and specimen collection. Contraceptive use by women on LNG implant was confirmed by palpation at visits 4 to 7. Women who were randomized to DMPA received repeat DMPA injections at visits 6 and 7. Baseline characteristics for women without HIV and WLHIV are listed in <xref rid="tab1" ref-type="table">Tables 1</xref> and <xref rid="tab2" ref-type="table">2</xref>.</p>
              </sec>
              <sec id="s4-2">
                <title>Specimen collection.</title>
                <p>Cervicovaginal samples were collected at visits 1, 2, 4, 5, 6, and 7. A catch-all swab was run along the posterior vaginal wall and placed immediately on ice with transfer within 2 h for storage at −80<bold>°</bold>C until processing for microbiota analysis. Cervicovaginal lavage (CVL) fluid was collected by washing the cervix, vaginal walls, and posterior fornix with 10 mL of phosphate-buffered saline (PBS) and then aspirating the pooled fluid (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B68" ref-type="bibr">68</xref>). The CVL was centrifuged, and the supernatant fluid was stored at −80<bold>°</bold>C for immune marker analysis. Collection of cervicovaginal samples was rescheduled if the woman had vaginal bleeding at the time of the study visit; if there were no days without bleeding during the study visit window, the sample was missed.</p>
              </sec>
              <sec id="s4-3">
                <title>Measurement of soluble immune mediators.</title>
                <p>The immune mediators were selected based on review of the relevant literature to ensure comparison of our results with prior and ongoing studies (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Longitudinal CVL samples were analyzed for (i) proinflammatory cytokines (interleukin-1α [IL-1α], IL-1 receptor α [IL-1Rα], IL-6, IL-8, IL-15, and tumor necrosis factor alpha [TNF-α]), (ii) CD4 T helper 1 (T<sub>H</sub>1) cytokines (IL-2, IL-12p40, IL-12p70, C-X-C motif chemokine-10 [CXCL-10], and gamma interferon [IFN-γ]), (iii) anti-inflammatory Th2 cytokines (IL-10 and IL-4), (iv) cytokines associated with monocyte activation (cluster of differentiation 163 [CD163], granulocyte-macrophage colony-stimulating factor [GM-CSF], and monocyte chemotactic protein 1 [MCP-1]), (v) chemokines (macrophage inflammatory protein-1β [MIP-1β] and RANTES), (vi) antiviral mediators (IFN-α), and (vii) antimicrobials (beta defensin 3 [BD3] and secretory leukocyte peptidase inhibitor [SLPI]). Except for CD163 (R&amp;D Systems, Minneapolis, MN), SLPI (R&amp;D Systems), and BD3 (Assay Biotechnology, Fremont, CA), which were measured by enzyme-linked immunosorbent assay (ELISA) (R&amp;D Systems), all markers were measured by a custom multiparameter bead array (Millipore, Billerica, MA) according to the manufacturer’s protocols. CVL samples were run undiluted, except for CXCL-10 and BD3, which were measured at a dilution of 1:10, and SLPI, which was measured at 1:200. Sample dilutions were determined by randomly selecting 3 samples that were tested in the various assays undiluted or at dilutions of 1:10, 1:100, 1:200, and 1:500. Concentrations that were below the lower limit of detection of the assay were reported as the value for the lower limit of detection for that immune mediator. IL-1Rα and IFN-α concentrations were not included in the statistical analysis because the vast majority of values fell above or below the standard curve, respectively, and as limited CVL volumes did not allow for testing a different dilution, concentrations could not be accurately quantified.</p>
              </sec>
              <sec id="s4-4">
                <title>Microbiota composition assessment.</title>
                <p>Total DNA from vaginal samples was isolated by the UNC Microbiome Core Facility using the Qiagen blood and tissue and QIAamp DNA stool protocols (Qiagen). PCR amplification of the V3-V4 region of the 16S rRNA gene was conducted using a protocol previously described and validated (<xref rid="B76" ref-type="bibr">76</xref>). Amplicons were pooled in equimolar concentrations and purified prior to loading on an Illumina HiSeq 2500 modified to generate 300-bp paired-end reads (<xref rid="B76" ref-type="bibr">76</xref>). Negative and positive-control samples were also as previously described (<xref rid="B76" ref-type="bibr">76</xref>). The sequences were demultiplexed using the dual-barcode strategy, with a mapping file linking barcode to samples and split_libraries.py, a QIIME-dependent script (<xref rid="B77" ref-type="bibr">77</xref>). The resulting forward and reverse fastq files were split by sample using the QIIME-dependent script split_sequence_file_on_sample_ids.py, and primer sequences were removed using TagCleaner (v.0.16) (<xref rid="B78" ref-type="bibr">78</xref>). Further processing followed the DADA2 Workflow for Big Data and dada2 (v.1.5.2) (<ext-link xlink:href="https://benjjneb.github.io/dada2/bigdata.html" ext-link-type="uri">https://benjjneb.github.io/dada2/bigdata.html</ext-link>) (<xref rid="B79" ref-type="bibr">79</xref>).</p>
                <p>Taxonomy was assigned to each amplicon sequence variant (ASV) generated by dada2 using the RDP Naïve Bayesian Classifier (<xref rid="B80" ref-type="bibr">80</xref>) trained with the SILVA 16S rRNA gene database (<xref rid="B81" ref-type="bibr">81</xref>). SpeciateIT (version 1.0; <ext-link xlink:href="https://github.com/ravel-lab/speciateIT" ext-link-type="uri">https://github.com/ravel-lab/speciateIT</ext-link>), a rapid per-sequence classifier, was used to assign species to the major genera. Sequence counts for ASVs assigned to the same taxonomy were summed for each sample. A table of sequence count assigned to each bacterial taxon for each sample was generated and used in statistical analyses. Bacterial taxa (<italic toggle="yes">n</italic> = 254) were filtered before analysis if observed in fewer than two samples or present at a frequency of less than 10<sup>−5</sup> study-wide (<italic toggle="yes">n</italic> = 169). CST assignments were performed using VALENCIA, a novel classifier that affords consistent CST assignment without clustering (<xref rid="B82" ref-type="bibr">82</xref>).</p>
                <p>Shannon diversity was calculated as previously reported (<xref rid="B26" ref-type="bibr">26</xref>).</p>
                <p>Quantification of 16S rRNA gene copy number and estimation of bacterial absolute abundance were performed as follows. The total number of 16S rRNA gene copies in each DNA sample was measured using the TaqMan BactQuant assay targeting the V3-V4 regions of the gene (<xref rid="B83" ref-type="bibr">83</xref>). The total number of 16S rRNA gene copies was expressed as number of copies per swab and used as an estimate of bacterial load (total count of bacterial cells present in a sample). An estimate of absolute abundance of each bacterial taxon was calculated for each sample by multiplying the total 16S rRNA gene copies obtained by quantitative PCR (qPCR) and the relative abundance of that taxa obtained by 16S rRNA gene sequencing.</p>
              </sec>
              <sec id="s4-5">
                <title>Statistical analysis.</title>
                <p>Women were grouped by HIV status stratified by HC type. To avoid potential contamination of microbiota or immune marker data by blood, we selected visit 2 as baseline for all analyses as these visits were scheduled to occur in the luteal phase and less likely to be acutely influenced by recent menses. Notably cycle timing was based on self-report only and not confirmed by hormone testing.</p>
                <p>For immune marker analysis, we present the median concentration ± 95% confidence interval (CI) for each marker. Data between women of different HIV status and/or HC use at the same visit were compared by Mann-Whitney test. Paired data (visit 4 versus visit 2 and visit 7 versus visit 2) of women in the same group based on HIV and HC status were analyzed by Wilcoxon matched-pair signed-rank test. Differences in immune mediator levels were statistically significant at an α of 0.05; to account for multiple comparisons, we applied the Benjamini-Hochberg method to calculate adjusted <italic toggle="yes">P</italic> values (<italic toggle="yes">P</italic> &lt; 0.0035) due to multiple comparisons increasing the false-discovery rate (FDR). All graphs were generated and statistical analyses performed with GraphPad Prism version 7 (La Jolla, CA).</p>
                <p>Fisher’s exact test was performed to test for differences in the vaginal microbiota between women with and without HIV at baseline (visit 2).</p>
                <p>The analysis of the dependence between the probability of DMPA and the change in the log<sub>10</sub> relative abundance of IL-12p40 at visit 7 versus visit 2 within the WHIV group was performed using the Baysian logistic regression adaptive spline model in R. The same method was applied to the analyses of the dependence between changes in the log<sub>10</sub> abundance of IL-12p40 and changes in the log<sub>10</sub> relative abundance of <italic toggle="yes">L. iners</italic> at visit 7 versus visit 2 in the WHIV group as well as in the WHIV-LNG and WHIV-DMPA subgroups of women.</p>
              </sec>
              <sec id="s4-6">
                <title>Ethical considerations.</title>
                <p>This study received ethical approval from the University of North Carolina Institutional Review Board (IRB), the Malawi National Health Sciences Research Committee, the Malawi Pharmacy Medicines and Poisons Board, and the IRB of the U.S. Centers for Disease Control and Prevention. The guidelines at all institutions strictly adhere to the World Medical Association’s Declaration of Helsinki.</p>
              </sec>
              <sec id="s4-7">
                <title>Data availability.</title>
                <p>Microbiome sequences have been submitted to the NCBI Sequence Read Archive.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank our study staff, the Lilongwe District Management Team, for their support of our study, and the Lighthouse Trust and Area 25 Health Centre for allowing us to inform potential participants about the study at their clinics.</p>
              <p>This study was funded by the following grants: CDC no. U48DP001944, CDC no. 200-2015-M-63021, NIH no. 1K01-TW009657-01, NIH no. P30-AI50410, Bill &amp; Melinda Gates Foundation no. OPP1090837, and USAID no. AID-OAA-A-15-00045. Analysis performed by K.D.P. was supported by the UNC Flow Cytometry Core, which is supported in part by Cancer Center Core support grant P30 CA016086 to the UNC Lineberger Comprehensive Cancer Center. Technical assistance was provided by the CFAR HIV/STD Laboratory Core, which is funded by NIH P30 AI050410. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.</p>
              <p>We declare no conflict of interest.</p>
            </ack>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Polis</surname><given-names>CB</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>KM</given-names></string-name>, <string-name><surname>Hannaford</surname><given-names>PC</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Chipato</surname><given-names>T</given-names></string-name>, <string-name><surname>Kiarie</surname><given-names>JN</given-names></string-name>, <string-name><surname>Westreich</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Steyn</surname><given-names>PS</given-names></string-name></person-group>. <year>2016</year>. <article-title>An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women</article-title>. <source>AIDS</source><volume>30</volume>:<fpage>2665</fpage>–<lpage>2683</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000001228</pub-id>.<pub-id pub-id-type="pmid">27500670</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morrison</surname><given-names>CS</given-names></string-name>, <string-name><surname>Chen</surname><given-names>PL</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>C</given-names></string-name>, <string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J</given-names></string-name>, <string-name><surname>Crook</surname><given-names>AM</given-names></string-name>, <string-name><surname>Van Damme</surname><given-names>L</given-names></string-name>, <string-name><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name>, <string-name><surname>Francis</surname><given-names>SC</given-names></string-name>, <string-name><surname>Friedland</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hayes</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Heffron</surname><given-names>R</given-names></string-name>, <string-name><surname>Kapiga</surname><given-names>S</given-names></string-name>, <string-name><surname>Karim</surname><given-names>QA</given-names></string-name>, <string-name><surname>Karpoff</surname><given-names>S</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>R</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RS</given-names></string-name>, <string-name><surname>McCormack</surname><given-names>S</given-names></string-name>, <string-name><surname>McGrath</surname><given-names>N</given-names></string-name>, <string-name><surname>Myer</surname><given-names>L</given-names></string-name>, <string-name><surname>Rees</surname><given-names>H</given-names></string-name>, <string-name><surname>van der Straten</surname><given-names>A</given-names></string-name>, <string-name><surname>Watson-Jones</surname><given-names>D</given-names></string-name>, <string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <string-name><surname>Stalter</surname><given-names>R</given-names></string-name>, <string-name><surname>Low</surname><given-names>N</given-names></string-name></person-group>. <year>2015</year>. <article-title>Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis</article-title>. <source>PLoS Med</source><volume>12</volume>:<elocation-id>e1001778</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1001778</pub-id>.<pub-id pub-id-type="pmid">25612136</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><collab>Evidence for Contraceptive Options and HIV Outcomes (ECHO) Consortium</collab>. <year>2019</year>. <article-title>HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial</article-title>. <source>Lancet</source><volume>394</volume>:<fpage>303</fpage>–<lpage>313</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)31288-7</pub-id>.<pub-id pub-id-type="pmid">31204114</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hapgood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>, <string-name><surname>Hel</surname><given-names>Z</given-names></string-name></person-group>. <year>2018</year>. <article-title>Hormonal contraception and HIV-1 acquisition: biological mechanisms</article-title>. <source>Endocr Rev</source><volume>39</volume>:<fpage>36</fpage>–<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1210/er.2017-00103</pub-id>.<pub-id pub-id-type="pmid">29309550</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szekeres-Bartho</surname><given-names>J</given-names></string-name>, <string-name><surname>Barakonyi</surname><given-names>A</given-names></string-name>, <string-name><surname>Par</surname><given-names>G</given-names></string-name>, <string-name><surname>Polgar</surname><given-names>B</given-names></string-name>, <string-name><surname>Palkovics</surname><given-names>T</given-names></string-name>, <string-name><surname>Szereday</surname><given-names>L</given-names></string-name></person-group>. <year>2001</year>. <article-title>Progesterone as an immunomodulatory molecule</article-title>. <source>Int Immunopharmacol</source><volume>1</volume>:<fpage>1037</fpage>–<lpage>1048</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1567-5769(01)00035-2</pub-id>.<pub-id pub-id-type="pmid">11407300</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Obendorf</surname><given-names>M</given-names></string-name>, <string-name><surname>Patchev</surname><given-names>VK</given-names></string-name></person-group>. <year>2004</year>. <article-title>Interactions of sex steroids with mechanisms of inflammation</article-title>. <source>Curr Drug Targets Inflamm Allergy</source><volume>3</volume>:<fpage>425</fpage>–<lpage>433</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1568010042634460</pub-id>.<pub-id pub-id-type="pmid">15584890</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hughes</surname><given-names>GC</given-names></string-name></person-group>. <year>2012</year>. <article-title>Progesterone and autoimmune disease</article-title>. <source>Autoimmun Rev</source><volume>11</volume>:<fpage>A502</fpage>–<lpage>A514</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2011.12.003</pub-id>.<pub-id pub-id-type="pmid">22193289</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname><given-names>IJ</given-names></string-name>, <string-name><surname>Peeva</surname><given-names>E</given-names></string-name>, <string-name><surname>Zandman-Goddard</surname><given-names>G</given-names></string-name></person-group>. <year>2015</year>. <article-title>Hormonal modulation of the immune system—a spotlight on the role of progestogens</article-title>. <source>Autoimmun Rev</source><volume>14</volume>:<fpage>536</fpage>–<lpage>542</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2015.02.004</pub-id>.<pub-id pub-id-type="pmid">25697984</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>OJ</given-names></string-name>, <string-name><surname>Klein</surname><given-names>SL</given-names></string-name></person-group>. <year>2017</year>. <article-title>Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites</article-title>. <source>Mucosal Immunol</source><volume>10</volume>:<fpage>1097</fpage>–<lpage>1107</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mi.2017.35</pub-id>.<pub-id pub-id-type="pmid">28401937</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burger</surname><given-names>HG</given-names></string-name>, <string-name><surname>Hale</surname><given-names>GE</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>DM</given-names></string-name>, <string-name><surname>Dennerstein</surname><given-names>L</given-names></string-name></person-group>. <year>2007</year>. <article-title>A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project</article-title>. <source>Hum Reprod Update</source><volume>13</volume>:<fpage>559</fpage>–<lpage>565</lpage>. doi:<pub-id pub-id-type="doi">10.1093/humupd/dmm020</pub-id>.<pub-id pub-id-type="pmid">17630397</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davis</surname><given-names>SR</given-names></string-name>, <string-name><surname>Lambrinoudaki</surname><given-names>I</given-names></string-name>, <string-name><surname>Lumsden</surname><given-names>M</given-names></string-name>, <string-name><surname>Mishra</surname><given-names>GD</given-names></string-name>, <string-name><surname>Pal</surname><given-names>L</given-names></string-name>, <string-name><surname>Rees</surname><given-names>M</given-names></string-name>, <string-name><surname>Santoro</surname><given-names>N</given-names></string-name>, <string-name><surname>Simoncini</surname><given-names>T</given-names></string-name></person-group>. <year>2015</year>. <article-title>Menopause</article-title>. <source>Nat Rev Dis Primers</source><volume>1</volume>:<fpage>15004</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrdp.2015.4</pub-id>.<pub-id pub-id-type="pmid">27188659</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ali</surname><given-names>ES</given-names></string-name>, <string-name><surname>Mangold</surname><given-names>C</given-names></string-name>, <string-name><surname>Peiris</surname><given-names>AN</given-names></string-name></person-group>. <year>2017</year>. <article-title>Estriol: emerging clinical benefits</article-title>. <source>Menopause</source><volume>24</volume>:<fpage>1081</fpage>–<lpage>1085</lpage>. doi:<pub-id pub-id-type="doi">10.1097/GME.0000000000000855</pub-id>.<pub-id pub-id-type="pmid">28375935</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piccinni</surname><given-names>MP</given-names></string-name>, <string-name><surname>Lombardelli</surname><given-names>L</given-names></string-name>, <string-name><surname>Logiodice</surname><given-names>F</given-names></string-name>, <string-name><surname>Kullolli</surname><given-names>O</given-names></string-name>, <string-name><surname>Parronchi</surname><given-names>P</given-names></string-name>, <string-name><surname>Romagnani</surname><given-names>S</given-names></string-name></person-group>. <year>2016</year>. <article-title>How pregnancy can affect autoimmune diseases progression?</article-title><source>Clin Mol Allergy</source><volume>14</volume>:<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12948-016-0048-x</pub-id>.<pub-id pub-id-type="pmid">27651750</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adar</surname><given-names>T</given-names></string-name>, <string-name><surname>Grisaru-Granovsky</surname><given-names>S</given-names></string-name>, <string-name><surname>Ben Ya'acov</surname><given-names>A</given-names></string-name>, <string-name><surname>Goldin</surname><given-names>E</given-names></string-name>, <string-name><surname>Bar-Gil Shitrit</surname><given-names>A</given-names></string-name></person-group>. <year>2015</year>. <article-title>Pregnancy and the immune system: general overview and the gastroenterological perspective</article-title>. <source>Dig Dis Sci</source><volume>60</volume>:<fpage>2581</fpage>–<lpage>2589</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10620-015-3683-z</pub-id>.<pub-id pub-id-type="pmid">25947331</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jara</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Medina</surname><given-names>G</given-names></string-name>, <string-name><surname>Cruz-Dominguez</surname><given-names>P</given-names></string-name>, <string-name><surname>Navarro</surname><given-names>C</given-names></string-name>, <string-name><surname>Vera-Lastra</surname><given-names>O</given-names></string-name>, <string-name><surname>Saavedra</surname><given-names>MA</given-names></string-name></person-group>. <year>2014</year>. <article-title>Risk factors of systemic lupus erythematosus flares during pregnancy</article-title>. <source>Immunol Res</source><volume>60</volume>:<fpage>184</fpage>–<lpage>192</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12026-014-8577-1</pub-id>.<pub-id pub-id-type="pmid">25391611</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luppi</surname><given-names>P</given-names></string-name></person-group>. <year>2003</year>. <article-title>How immune mechanisms are affected by pregnancy</article-title>. <source>Vaccine</source><volume>21</volume>:<fpage>3352</fpage>–<lpage>3357</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0264-410x(03)00331-1</pub-id>.<pub-id pub-id-type="pmid">12850338</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilder</surname><given-names>RL</given-names></string-name></person-group>. <year>1998</year>. <article-title>Hormones, pregnancy, and autoimmune diseases</article-title>. <source>Ann N Y Acad Sci</source><volume>840</volume>:<fpage>45</fpage>–<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09547.x</pub-id>.<pub-id pub-id-type="pmid">9629235</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hel</surname><given-names>Z</given-names></string-name>, <string-name><surname>Stringer</surname><given-names>E</given-names></string-name>, <string-name><surname>Mestecky</surname><given-names>J</given-names></string-name></person-group>. <year>2010</year>. <article-title>Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection</article-title>. <source>Endocr Rev</source><volume>31</volume>:<fpage>79</fpage>–<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1210/er.2009-0018</pub-id>.<pub-id pub-id-type="pmid">19903932</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Achilles</surname><given-names>SL</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name></person-group>. <year>2013</year>. <article-title>The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota</article-title>. <source>AIDS</source><volume>27</volume>(<issue>Suppl 1</issue>):<fpage>S5</fpage>–<lpage>S15</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000000058</pub-id>.<pub-id pub-id-type="pmid">24088684</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname><given-names>L</given-names></string-name>, <string-name><surname>Patton</surname><given-names>DL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>A</given-names></string-name>, <string-name><surname>Thwin</surname><given-names>SS</given-names></string-name>, <string-name><surname>Hooton</surname><given-names>TM</given-names></string-name>, <string-name><surname>Eschenbach</surname><given-names>DA</given-names></string-name></person-group>. <year>2000</year>. <article-title>Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium</article-title>. <source>Obstet Gynecol</source><volume>96</volume>:<fpage>431</fpage>–<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0029-7844(00)00906-6</pub-id>.<pub-id pub-id-type="pmid">10960638</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huijbregts</surname><given-names>RP</given-names></string-name>, <string-name><surname>Helton</surname><given-names>ES</given-names></string-name>, <string-name><surname>Michel</surname><given-names>KG</given-names></string-name>, <string-name><surname>Sabbaj</surname><given-names>S</given-names></string-name>, <string-name><surname>Richter</surname><given-names>HE</given-names></string-name>, <string-name><surname>Goepfert</surname><given-names>PA</given-names></string-name>, <string-name><surname>Hel</surname><given-names>Z</given-names></string-name></person-group>. <year>2013</year>. <article-title>Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms</article-title>. <source>Endocrinology</source><volume>154</volume>:<fpage>1282</fpage>–<lpage>1295</lpage>. doi:<pub-id pub-id-type="doi">10.1210/en.2012-1850</pub-id>.<pub-id pub-id-type="pmid">23354099</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cabrera-Munoz</surname><given-names>E</given-names></string-name>, <string-name><surname>Fuentes-Romero</surname><given-names>LL</given-names></string-name>, <string-name><surname>Zamora-Chavez</surname><given-names>J</given-names></string-name>, <string-name><surname>Camacho-Arroyo</surname><given-names>I</given-names></string-name>, <string-name><surname>Soto-Ramirez</surname><given-names>LE</given-names></string-name></person-group>. <year>2012</year>. <article-title>Effects of progesterone on the content of CCR5 and CXCR4 coreceptors in PBMCs of seropositive and exposed but uninfected Mexican women to HIV-1</article-title>. <source>J Steroid Biochem Mol Biol</source><volume>132</volume>:<fpage>66</fpage>–<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.02.001</pub-id>.<pub-id pub-id-type="pmid">22342838</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>EH</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>KE</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>BA</given-names></string-name>, <string-name><surname>Yamamoto</surname><given-names>HS</given-names></string-name>, <string-name><surname>Soumillon</surname><given-names>M</given-names></string-name>, <string-name><surname>Padavattan</surname><given-names>N</given-names></string-name>, <string-name><surname>Ismail</surname><given-names>N</given-names></string-name>, <string-name><surname>Moodley</surname><given-names>A</given-names></string-name>, <string-name><surname>Sabatini</surname><given-names>ME</given-names></string-name>, <string-name><surname>Ghebremichael</surname><given-names>MS</given-names></string-name>, <string-name><surname>Nusbaum</surname><given-names>C</given-names></string-name>, <string-name><surname>Huttenhower</surname><given-names>C</given-names></string-name>, <string-name><surname>Virgin</surname><given-names>HW</given-names></string-name>, <string-name><surname>Ndung'u</surname><given-names>T</given-names></string-name>, <string-name><surname>Dong</surname><given-names>KL</given-names></string-name>, <string-name><surname>Walker</surname><given-names>BD</given-names></string-name>, <string-name><surname>Fichorova</surname><given-names>RN</given-names></string-name>, <string-name><surname>Kwon</surname><given-names>DS</given-names></string-name></person-group>. <year>2015</year>. <article-title>Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract</article-title>. <source>Immunity</source><volume>42</volume>:<fpage>965</fpage>–<lpage>976</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2015.04.019</pub-id>.<pub-id pub-id-type="pmid">25992865</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gosmann</surname><given-names>C</given-names></string-name>, <string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Handley</surname><given-names>SA</given-names></string-name>, <string-name><surname>Farcasanu</surname><given-names>M</given-names></string-name>, <string-name><surname>Abu-Ali</surname><given-names>G</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>BA</given-names></string-name>, <string-name><surname>Padavattan</surname><given-names>N</given-names></string-name>, <string-name><surname>Desai</surname><given-names>C</given-names></string-name>, <string-name><surname>Droit</surname><given-names>L</given-names></string-name>, <string-name><surname>Moodley</surname><given-names>A</given-names></string-name>, <string-name><surname>Dong</surname><given-names>M</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ismail</surname><given-names>N</given-names></string-name>, <string-name><surname>Ndung'u</surname><given-names>T</given-names></string-name>, <string-name><surname>Ghebremichael</surname><given-names>MS</given-names></string-name>, <string-name><surname>Wesemann</surname><given-names>DR</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>C</given-names></string-name>, <string-name><surname>Dong</surname><given-names>KL</given-names></string-name>, <string-name><surname>Huttenhower</surname><given-names>C</given-names></string-name>, <string-name><surname>Walker</surname><given-names>BD</given-names></string-name>, <string-name><surname>Virgin</surname><given-names>HW</given-names></string-name>, <string-name><surname>Kwon</surname><given-names>DS</given-names></string-name></person-group>. <year>2017</year>. <article-title>Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women</article-title>. <source>Immunity</source><volume>46</volume>:<fpage>29</fpage>–<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2016.12.013</pub-id>.<pub-id pub-id-type="pmid">28087240</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname><given-names>CM</given-names></string-name>, <string-name><surname>McLemore</surname><given-names>L</given-names></string-name>, <string-name><surname>Westerberg</surname><given-names>K</given-names></string-name>, <string-name><surname>Astronomo</surname><given-names>R</given-names></string-name>, <string-name><surname>Smythe</surname><given-names>K</given-names></string-name>, <string-name><surname>Gardella</surname><given-names>C</given-names></string-name>, <string-name><surname>Mack</surname><given-names>M</given-names></string-name>, <string-name><surname>Magaret</surname><given-names>A</given-names></string-name>, <string-name><surname>Patton</surname><given-names>D</given-names></string-name>, <string-name><surname>Agnew</surname><given-names>K</given-names></string-name>, <string-name><surname>McElrath</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Hladik</surname><given-names>F</given-names></string-name>, <string-name><surname>Eschenbach</surname><given-names>D</given-names></string-name></person-group>. <year>2014</year>. <article-title>Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells</article-title>. <source>J Infect Dis</source><volume>210</volume>:<fpage>651</fpage>–<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiu176</pub-id>.<pub-id pub-id-type="pmid">24652495</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ravel</surname><given-names>J</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, <string-name><surname>Abdo</surname><given-names>Z</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>GM</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>SS</given-names></string-name>, <string-name><surname>McCulle</surname><given-names>SL</given-names></string-name>, <string-name><surname>Karlebach</surname><given-names>S</given-names></string-name>, <string-name><surname>Gorle</surname><given-names>R</given-names></string-name>, <string-name><surname>Russell</surname><given-names>J</given-names></string-name>, <string-name><surname>Tacket</surname><given-names>CO</given-names></string-name>, <string-name><surname>Brotman</surname><given-names>RM</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CC</given-names></string-name>, <string-name><surname>Ault</surname><given-names>K</given-names></string-name>, <string-name><surname>Peralta</surname><given-names>L</given-names></string-name>, <string-name><surname>Forney</surname><given-names>LJ</given-names></string-name></person-group>. <year>2011</year>. <article-title>Vaginal microbiome of reproductive-age women</article-title>. <source>Proc Natl Acad Sci USA</source><volume>108</volume>(<issue>Suppl 1</issue>):<fpage>4680</fpage>–<lpage>4687</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1002611107</pub-id>.<pub-id pub-id-type="pmid">20534435</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Linhares</surname><given-names>IM</given-names></string-name>, <string-name><surname>Summers</surname><given-names>PR</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>B</given-names></string-name>, <string-name><surname>Giraldo</surname><given-names>PC</given-names></string-name>, <string-name><surname>Witkin</surname><given-names>SS</given-names></string-name></person-group>. <year>2011</year>. <article-title>Contemporary perspectives on vaginal pH and lactobacilli</article-title>. <source>Am J Obstet Gynecol</source><volume>204</volume>:<fpage>120.e1</fpage>–<lpage>120.e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajog.2010.07.010</pub-id>.</mixed-citation>
              </ref>
              <ref id="B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O'Hanlon</surname><given-names>DE</given-names></string-name>, <string-name><surname>Moench</surname><given-names>TR</given-names></string-name>, <string-name><surname>Cone</surname><given-names>RA</given-names></string-name></person-group>. <year>2013</year>. <article-title>Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e80074</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0080074</pub-id>.<pub-id pub-id-type="pmid">24223212</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peebles</surname><given-names>K</given-names></string-name>, <string-name><surname>Velloza</surname><given-names>J</given-names></string-name>, <string-name><surname>Balkus</surname><given-names>JE</given-names></string-name>, <string-name><surname>Mcclelland</surname><given-names>RS</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>RV</given-names></string-name></person-group>. <year>2019</year>. <article-title>High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis</article-title>. <source>Sex Transm Dis</source><volume>46</volume>:<fpage>304</fpage>–<lpage>311</lpage>. doi:<pub-id pub-id-type="doi">10.1097/OLQ.0000000000000972</pub-id>.<pub-id pub-id-type="pmid">30624309</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Price</surname><given-names>JT</given-names></string-name>, <string-name><surname>Vwalika</surname><given-names>B</given-names></string-name>, <string-name><surname>Hobbs</surname><given-names>M</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>JAE</given-names></string-name>, <string-name><surname>Stringer</surname><given-names>EM</given-names></string-name>, <string-name><surname>Zou</surname><given-names>F</given-names></string-name>, <string-name><surname>Rittenhouse</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Azcarate-Peril</surname><given-names>A</given-names></string-name>, <string-name><surname>Kasaro</surname><given-names>MP</given-names></string-name>, <string-name><surname>Stringer</surname><given-names>JSA</given-names></string-name></person-group>. <year>2019</year>. <article-title>Highly diverse anaerobe-predominant vaginal microbiota among HIV-infected pregnant women in Zambia</article-title>. <source>PLoS One</source><volume>14</volume>:<elocation-id>e0223128</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0223128</pub-id>.<pub-id pub-id-type="pmid">31577818</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Odogwu</surname><given-names>NM</given-names></string-name>, <string-name><surname>Onebunne</surname><given-names>CA</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Ayeni</surname><given-names>FA</given-names></string-name>, <string-name><surname>Walther-Antonio</surname><given-names>MRS</given-names></string-name>, <string-name><surname>Olayemi</surname><given-names>OO</given-names></string-name>, <string-name><surname>Chia</surname><given-names>N</given-names></string-name>, <string-name><surname>Omigbodun</surname><given-names>AO</given-names></string-name></person-group>. <year>2021</year>. <article-title>Lactobacillus crispatus thrives in pregnancy hormonal milieu in a Nigerian patient cohort</article-title>. <source>Sci Rep</source><volume>11</volume>:<fpage>18152</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-96339-y</pub-id>.<pub-id pub-id-type="pmid">34518588</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fettweis</surname><given-names>JM</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>JP</given-names></string-name>, <string-name><surname>Serrano</surname><given-names>MG</given-names></string-name>, <string-name><surname>Sheth</surname><given-names>NU</given-names></string-name>, <string-name><surname>Girerd</surname><given-names>PH</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Strauss</surname><given-names>JF</given-names></string-name>, <collab>Vaginal Microbiome Consortium</collab>, <string-name><surname>Jefferson</surname><given-names>KK</given-names></string-name>, <string-name><surname>Buck</surname><given-names>GA</given-names></string-name></person-group>. <year>2014</year>. <article-title>Differences in vaginal microbiome in African American women versus women of European ancestry</article-title>. <source>Microbiology (Reading)</source><volume>160</volume>:<fpage>2272</fpage>–<lpage>2282</lpage>. doi:<pub-id pub-id-type="doi">10.1099/mic.0.081034-0</pub-id>.<pub-id pub-id-type="pmid">25073854</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautam</surname><given-names>R</given-names></string-name>, <string-name><surname>Borgdorff</surname><given-names>H</given-names></string-name>, <string-name><surname>Jespers</surname><given-names>V</given-names></string-name>, <string-name><surname>Francis</surname><given-names>SC</given-names></string-name>, <string-name><surname>Verhelst</surname><given-names>R</given-names></string-name>, <string-name><surname>Mwaura</surname><given-names>M</given-names></string-name>, <string-name><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name>, <string-name><surname>Ndayisaba</surname><given-names>G</given-names></string-name>, <string-name><surname>Kyongo</surname><given-names>JK</given-names></string-name>, <string-name><surname>Hardy</surname><given-names>L</given-names></string-name>, <string-name><surname>Menten</surname><given-names>J</given-names></string-name>, <string-name><surname>Crucitti</surname><given-names>T</given-names></string-name>, <string-name><surname>Tsivtsivadze</surname><given-names>E</given-names></string-name>, <string-name><surname>Schuren</surname><given-names>F</given-names></string-name>, <string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <collab>Vaginal Biomarkers Study Group</collab></person-group>. <year>2015</year>. <article-title>Correlates of the molecular vaginal microbiota composition of African women</article-title>. <source>BMC Infect Dis</source><volume>15</volume>:<fpage>86</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-015-0831-1</pub-id>.<pub-id pub-id-type="pmid">25887567</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brotman</surname><given-names>RM</given-names></string-name></person-group>. <year>2011</year>. <article-title>Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective</article-title>. <source>J Clin Invest</source><volume>121</volume>:<fpage>4610</fpage>–<lpage>4617</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI57172</pub-id>.<pub-id pub-id-type="pmid">22133886</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cho</surname><given-names>HW</given-names></string-name>, <string-name><surname>Eom</surname><given-names>YB</given-names></string-name></person-group>. <year>2021</year>. <article-title>Forensic analysis of human microbiome in skin and body fluids based on geographic location</article-title>. <source>Front Cell Infect Microbiol</source><volume>11</volume>:<fpage>695191</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2021.695191</pub-id>.<pub-id pub-id-type="pmid">34458160</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>SD</given-names></string-name>, <string-name><surname>Acharya</surname><given-names>KD</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>JE</given-names></string-name>, <string-name><surname>Deveney</surname><given-names>CM</given-names></string-name>, <string-name><surname>Walther-Antonio</surname><given-names>MRS</given-names></string-name>, <string-name><surname>Tetel</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Chia</surname><given-names>N</given-names></string-name></person-group>. <year>2020</year>. <article-title>Daily vaginal microbiota fluctuations associated with natural hormonal cycle, contraceptives, diet, and exercise</article-title>. <source>mSphere</source><volume>5</volume>:<elocation-id>e00593-20</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSphere.00593-20</pub-id>.<pub-id pub-id-type="pmid">32641429</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bradley</surname><given-names>F</given-names></string-name>, <string-name><surname>Birse</surname><given-names>K</given-names></string-name>, <string-name><surname>Hasselrot</surname><given-names>K</given-names></string-name>, <string-name><surname>Noel-Romas</surname><given-names>L</given-names></string-name>, <string-name><surname>Introini</surname><given-names>A</given-names></string-name>, <string-name><surname>Wefer</surname><given-names>H</given-names></string-name>, <string-name><surname>Seifert</surname><given-names>M</given-names></string-name>, <string-name><surname>Engstrand</surname><given-names>L</given-names></string-name>, <string-name><surname>Tjernlund</surname><given-names>A</given-names></string-name>, <string-name><surname>Broliden</surname><given-names>K</given-names></string-name>, <string-name><surname>Burgener</surname><given-names>AD</given-names></string-name></person-group>. <year>2018</year>. <article-title>The vaginal microbiome amplifies sex hormone-associated cyclic changes in cervicovaginal inflammation and epithelial barrier disruption</article-title>. <source>Am J Reprod Immunol</source><volume>80</volume>:<elocation-id>e12863</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/aji.12863</pub-id>.<pub-id pub-id-type="pmid">29709092</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratten</surname><given-names>LK</given-names></string-name>, <string-name><surname>Plummer</surname><given-names>EL</given-names></string-name>, <string-name><surname>Bradshaw</surname><given-names>CS</given-names></string-name>, <string-name><surname>Fairley</surname><given-names>CK</given-names></string-name>, <string-name><surname>Murray</surname><given-names>GL</given-names></string-name>, <string-name><surname>Garland</surname><given-names>SM</given-names></string-name>, <string-name><surname>Bateson</surname><given-names>D</given-names></string-name>, <string-name><surname>Tachedjian</surname><given-names>G</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Vodstrcil</surname><given-names>LA</given-names></string-name></person-group>. <year>2021</year>. <article-title>The effect of exogenous sex steroids on the vaginal microbiota: a systematic review</article-title>. <source>Front Cell Infect Microbiol</source><volume>11</volume>:<fpage>732423</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2021.732423</pub-id>.<pub-id pub-id-type="pmid">34869054</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratten</surname><given-names>LK</given-names></string-name>, <string-name><surname>Plummer</surname><given-names>EL</given-names></string-name>, <string-name><surname>Murray</surname><given-names>GL</given-names></string-name>, <string-name><surname>Danielewski</surname><given-names>J</given-names></string-name>, <string-name><surname>Fairley</surname><given-names>CK</given-names></string-name>, <string-name><surname>Garland</surname><given-names>SM</given-names></string-name>, <string-name><surname>Hocking</surname><given-names>JS</given-names></string-name>, <string-name><surname>Tachedjian</surname><given-names>G</given-names></string-name>, <string-name><surname>Chow</surname><given-names>E</given-names></string-name>, <string-name><surname>Bradshaw</surname><given-names>CS</given-names></string-name>, <string-name><surname>Vodstrcil</surname><given-names>LA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study</article-title>. <source>BJOG</source><volume>128</volume>:<fpage>756</fpage>–<lpage>767</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1471-0528.16430</pub-id>.<pub-id pub-id-type="pmid">33480468</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sabo</surname><given-names>MC</given-names></string-name>, <string-name><surname>Balkus</surname><given-names>JE</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>BA</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Kimani</surname><given-names>J</given-names></string-name>, <string-name><surname>Anzala</surname><given-names>O</given-names></string-name>, <string-name><surname>Schwebke</surname><given-names>J</given-names></string-name>, <string-name><surname>Feidler</surname><given-names>TL</given-names></string-name>, <string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RS</given-names></string-name></person-group>. <year>2019</year>. <article-title>Association between vaginal washing and vaginal bacterial concentrations</article-title>. <source>PLoS One</source><volume>14</volume>:<elocation-id>e0210825</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0210825</pub-id>.<pub-id pub-id-type="pmid">30677048</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Amsel</surname><given-names>R</given-names></string-name>, <string-name><surname>Totten</surname><given-names>PA</given-names></string-name>, <string-name><surname>Spiegel</surname><given-names>CA</given-names></string-name>, <string-name><surname>Chen</surname><given-names>KC</given-names></string-name>, <string-name><surname>Eschenbach</surname><given-names>D</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>KK</given-names></string-name></person-group>. <year>1983</year>. <article-title>Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations</article-title>. <source>Am J Med</source><volume>74</volume>:<fpage>14</fpage>–<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0002-9343(83)91112-9</pub-id>.<pub-id pub-id-type="pmid">6600371</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nugent</surname><given-names>RP</given-names></string-name>, <string-name><surname>Krohn</surname><given-names>MA</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name></person-group>. <year>1991</year>. <article-title>Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation</article-title>. <source>J Clin Microbiol</source><volume>29</volume>:<fpage>297</fpage>–<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jcm.29.2.297-301.1991</pub-id>.<pub-id pub-id-type="pmid">1706728</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pybus</surname><given-names>V</given-names></string-name>, <string-name><surname>Onderdonk</surname><given-names>AB</given-names></string-name></person-group>. <year>1999</year>. <article-title>Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis</article-title>. <source>Microbes Infect</source><volume>1</volume>:<fpage>285</fpage>–<lpage>292</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1286-4579(99)80024-0</pub-id>.<pub-id pub-id-type="pmid">10602662</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name>, <string-name><surname>Fiedler</surname><given-names>TL</given-names></string-name>, <string-name><surname>Marrazzo</surname><given-names>JM</given-names></string-name></person-group>. <year>2005</year>. <article-title>Molecular identification of bacteria associated with bacterial vaginosis</article-title>. <source>N Engl J Med</source><volume>353</volume>:<fpage>1899</fpage>–<lpage>1911</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa043802</pub-id>.<pub-id pub-id-type="pmid">16267321</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marrazzo</surname><given-names>JM</given-names></string-name>, <string-name><surname>Martin</surname><given-names>DH</given-names></string-name>, <string-name><surname>Watts</surname><given-names>DH</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>J</given-names></string-name>, <string-name><surname>Sobel</surname><given-names>JD</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name>, <string-name><surname>Deal</surname><given-names>C</given-names></string-name>, <string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name></person-group>. <year>2010</year>. <article-title>Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID</article-title>. <source>Sex Transm Dis</source><volume>37</volume>:<fpage>732</fpage>–<lpage>744</lpage>. doi:<pub-id pub-id-type="doi">10.1097/OLQ.0b013e3181fbbc95</pub-id>.<pub-id pub-id-type="pmid">21068695</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oakley</surname><given-names>BB</given-names></string-name>, <string-name><surname>Fiedler</surname><given-names>TL</given-names></string-name>, <string-name><surname>Marrazzo</surname><given-names>JM</given-names></string-name>, <string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name></person-group>. <year>2008</year>. <article-title>Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis</article-title>. <source>Appl Environ Microbiol</source><volume>74</volume>:<fpage>4898</fpage>–<lpage>4909</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.02884-07</pub-id>.<pub-id pub-id-type="pmid">18487399</pub-id></mixed-citation>
              </ref>
              <ref id="B47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spiegel</surname><given-names>CA</given-names></string-name></person-group>. <year>1991</year>. <article-title>Bacterial vaginosis</article-title>. <source>Clin Microbiol Rev</source><volume>4</volume>:<fpage>485</fpage>–<lpage>502</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.4.4.485</pub-id>.<pub-id pub-id-type="pmid">1747864</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>, <string-name><surname>Achilles</surname><given-names>S</given-names></string-name>, <string-name><surname>Bradshaw</surname><given-names>CS</given-names></string-name>, <string-name><surname>Burgener</surname><given-names>A</given-names></string-name>, <string-name><surname>Crucitti</surname><given-names>T</given-names></string-name>, <string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name>, <string-name><surname>Jaspan</surname><given-names>HB</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>R</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>, <string-name><surname>Klatt</surname><given-names>N</given-names></string-name>, <string-name><surname>Kwon</surname><given-names>DS</given-names></string-name>, <string-name><surname>Marrazzo</surname><given-names>JM</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>S</given-names></string-name>, <string-name><surname>Ravel</surname><given-names>J</given-names></string-name>, <string-name><surname>van de Wijgert</surname><given-names>J</given-names></string-name>, <string-name><surname>Vodstrcil</surname><given-names>LA</given-names></string-name>, <string-name><surname>Tachedjian</surname><given-names>G</given-names></string-name></person-group>. <year>2019</year>. <article-title>The evolving facets of bacterial vaginosis: implications for HIV transmission</article-title>. <source>AIDS Res Hum Retroviruses</source><volume>35</volume>:<fpage>219</fpage>–<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1089/AID.2018.0304</pub-id>.<pub-id pub-id-type="pmid">30638028</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bayigga</surname><given-names>L</given-names></string-name>, <string-name><surname>Kateete</surname><given-names>DP</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Sekikubo</surname><given-names>M</given-names></string-name>, <string-name><surname>Nakanjako</surname><given-names>D</given-names></string-name></person-group>. <year>2019</year>. <article-title>Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention</article-title>. <source>Am J Obstet Gynecol</source><volume>220</volume>:<fpage>155</fpage>–<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajog.2018.10.014</pub-id>.<pub-id pub-id-type="pmid">30321529</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kyongo</surname><given-names>JK</given-names></string-name>, <string-name><surname>Crucitti</surname><given-names>T</given-names></string-name>, <string-name><surname>Menten</surname><given-names>J</given-names></string-name>, <string-name><surname>Hardy</surname><given-names>L</given-names></string-name>, <string-name><surname>Cools</surname><given-names>P</given-names></string-name>, <string-name><surname>Michiels</surname><given-names>J</given-names></string-name>, <string-name><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name>, <string-name><surname>Mwaura</surname><given-names>M</given-names></string-name>, <string-name><surname>Ndayisaba</surname><given-names>G</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>S</given-names></string-name>, <string-name><surname>Fichorova</surname><given-names>R</given-names></string-name>, <string-name><surname>van de Wijgert</surname><given-names>J</given-names></string-name>, <string-name><surname>Vanham</surname><given-names>G</given-names></string-name>, <string-name><surname>Arien</surname><given-names>KK</given-names></string-name>, <string-name><surname>Jespers</surname><given-names>V</given-names></string-name></person-group>. <year>2015</year>. <article-title>Cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in sub-Saharan African women, with relevance to HIV risk and prevention</article-title>. <source>Clin Vaccine Immunol</source><volume>22</volume>:<fpage>526</fpage>–<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CVI.00762-14</pub-id>.<pub-id pub-id-type="pmid">25761460</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lennard</surname><given-names>K</given-names></string-name>, <string-name><surname>Dabee</surname><given-names>S</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>SL</given-names></string-name>, <string-name><surname>Havyarimana</surname><given-names>E</given-names></string-name>, <string-name><surname>Blakney</surname><given-names>A</given-names></string-name>, <string-name><surname>Jaumdally</surname><given-names>SZ</given-names></string-name>, <string-name><surname>Botha</surname><given-names>G</given-names></string-name>, <string-name><surname>Mkhize</surname><given-names>NN</given-names></string-name>, <string-name><surname>Bekker</surname><given-names>LG</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>DA</given-names></string-name>, <string-name><surname>Gray</surname><given-names>G</given-names></string-name>, <string-name><surname>Mulder</surname><given-names>N</given-names></string-name>, <string-name><surname>Passmore</surname><given-names>JS</given-names></string-name>, <string-name><surname>Jaspan</surname><given-names>HB</given-names></string-name></person-group>. <year>2018</year>. <article-title>Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females</article-title>. <source>Infect Immun</source><volume>86</volume>:<elocation-id>e00410-17</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/IAI.00410-17</pub-id>.<pub-id pub-id-type="pmid">29038128</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lokken</surname><given-names>EM</given-names></string-name>, <string-name><surname>Balkus</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kiarie</surname><given-names>J</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>JP</given-names></string-name>, <string-name><surname>Jaoko</surname><given-names>W</given-names></string-name>, <string-name><surname>Totten</surname><given-names>PA</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RS</given-names></string-name>, <string-name><surname>Manhart</surname><given-names>LE</given-names></string-name></person-group>. <year>2017</year>. <article-title>Association of recent bacterial vaginosis with acquisition of Mycoplasma genitalium</article-title>. <source>Am J Epidemiol</source><volume>186</volume>:<fpage>194</fpage>–<lpage>201</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kwx043</pub-id>.<pub-id pub-id-type="pmid">28472225</pub-id></mixed-citation>
              </ref>
              <ref id="B53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martin</surname><given-names>HL</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>BA</given-names></string-name>, <string-name><surname>Nyange</surname><given-names>PM</given-names></string-name>, <string-name><surname>Lavreys</surname><given-names>L</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name>, <string-name><surname>Chohan</surname><given-names>B</given-names></string-name>, <string-name><surname>Mandaliya</surname><given-names>K</given-names></string-name>, <string-name><surname>Ndinya-Achola</surname><given-names>JO</given-names></string-name>, <string-name><surname>Bwayo</surname><given-names>J</given-names></string-name>, <string-name><surname>Kreiss</surname><given-names>J</given-names></string-name></person-group>. <year>1999</year>. <article-title>Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition</article-title>. <source>J Infect Dis</source><volume>180</volume>:<fpage>1863</fpage>–<lpage>1868</lpage>. doi:<pub-id pub-id-type="doi">10.1086/315127</pub-id>.<pub-id pub-id-type="pmid">10558942</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taha</surname><given-names>TE</given-names></string-name>, <string-name><surname>Hoover</surname><given-names>DR</given-names></string-name>, <string-name><surname>Dallabetta</surname><given-names>GA</given-names></string-name>, <string-name><surname>Kumwenda</surname><given-names>NI</given-names></string-name>, <string-name><surname>Mtimavalye</surname><given-names>LA</given-names></string-name>, <string-name><surname>Yang</surname><given-names>LP</given-names></string-name>, <string-name><surname>Liomba</surname><given-names>GN</given-names></string-name>, <string-name><surname>Broadhead</surname><given-names>RL</given-names></string-name>, <string-name><surname>Chiphangwi</surname><given-names>JD</given-names></string-name>, <string-name><surname>Miotti</surname><given-names>PG</given-names></string-name></person-group>. <year>1998</year>. <article-title>Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV</article-title>. <source>AIDS</source><volume>12</volume>:<fpage>1699</fpage>–<lpage>1706</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00002030-199813000-00019</pub-id>.<pub-id pub-id-type="pmid">9764791</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>CS</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>C</given-names></string-name>, <string-name><surname>Van Der Pol</surname><given-names>B</given-names></string-name>, <string-name><surname>Chipato</surname><given-names>T</given-names></string-name>, <string-name><surname>Byamugisha</surname><given-names>JK</given-names></string-name>, <string-name><surname>Padian</surname><given-names>N</given-names></string-name>, <string-name><surname>Salata</surname><given-names>RA</given-names></string-name></person-group>. <year>2009</year>. <article-title>Disentangling contributions of reproductive tract infections to HIV acquisition in African women</article-title>. <source>Sex Transm Dis</source><volume>36</volume>:<fpage>357</fpage>–<lpage>364</lpage>. doi:<pub-id pub-id-type="doi">10.1097/OLQ.0b013e3181a4f695</pub-id>.<pub-id pub-id-type="pmid">19434010</pub-id></mixed-citation>
              </ref>
              <ref id="B56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrova</surname><given-names>MI</given-names></string-name>, <string-name><surname>van den Broek</surname><given-names>M</given-names></string-name>, <string-name><surname>Balzarini</surname><given-names>J</given-names></string-name>, <string-name><surname>Vanderleyden</surname><given-names>J</given-names></string-name>, <string-name><surname>Lebeer</surname><given-names>S</given-names></string-name></person-group>. <year>2013</year>. <article-title>Vaginal microbiota and its role in HIV transmission and infection</article-title>. <source>FEMS Microbiol Rev</source><volume>37</volume>:<fpage>762</fpage>–<lpage>792</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1574-6976.12029</pub-id>.<pub-id pub-id-type="pmid">23789590</pub-id></mixed-citation>
              </ref>
              <ref id="B57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <string-name><surname>Borgdorff</surname><given-names>H</given-names></string-name>, <string-name><surname>Verhelst</surname><given-names>R</given-names></string-name>, <string-name><surname>Crucitti</surname><given-names>T</given-names></string-name>, <string-name><surname>Francis</surname><given-names>S</given-names></string-name>, <string-name><surname>Verstraelen</surname><given-names>H</given-names></string-name>, <string-name><surname>Jespers</surname><given-names>V</given-names></string-name></person-group>. <year>2014</year>. <article-title>The vaginal microbiota: what have we learned after a decade of molecular characterization?</article-title><source>PLoS One</source><volume>9</volume>:<elocation-id>e105998</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0105998</pub-id>.<pub-id pub-id-type="pmid">25148517</pub-id></mixed-citation>
              </ref>
              <ref id="B58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thurman</surname><given-names>AR</given-names></string-name>, <string-name><surname>Kimble</surname><given-names>T</given-names></string-name>, <string-name><surname>Herold</surname><given-names>B</given-names></string-name>, <string-name><surname>Mesquita</surname><given-names>PM</given-names></string-name>, <string-name><surname>Fichorova</surname><given-names>RN</given-names></string-name>, <string-name><surname>Dawood</surname><given-names>HY</given-names></string-name>, <string-name><surname>Fashemi</surname><given-names>T</given-names></string-name>, <string-name><surname>Chandra</surname><given-names>N</given-names></string-name>, <string-name><surname>Rabe</surname><given-names>L</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>TD</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>S</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>J</given-names></string-name>, <string-name><surname>Doncel</surname><given-names>G</given-names></string-name></person-group>. <year>2015</year>. <article-title>Bacterial vaginosis and subclinical markers of genital tract inflammation and mucosal immunity</article-title>. <source>AIDS Res Hum Retroviruses</source><volume>31</volume>:<fpage>1139</fpage>–<lpage>1152</lpage>. doi:<pub-id pub-id-type="doi">10.1089/aid.2015.0006</pub-id>.<pub-id pub-id-type="pmid">26204200</pub-id></mixed-citation>
              </ref>
              <ref id="B59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Armstrong</surname><given-names>E</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>R</given-names></string-name></person-group>. <year>2021</year>. <article-title>Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk</article-title>. <source>Microbiome</source><volume>9</volume>:<fpage>239</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-021-01183-x</pub-id>.<pub-id pub-id-type="pmid">34893070</pub-id></mixed-citation>
              </ref>
              <ref id="B60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alisoltani</surname><given-names>A</given-names></string-name>, <string-name><surname>Manhanzva</surname><given-names>MT</given-names></string-name>, <string-name><surname>Potgieter</surname><given-names>M</given-names></string-name>, <string-name><surname>Balle</surname><given-names>C</given-names></string-name>, <string-name><surname>Bell</surname><given-names>L</given-names></string-name>, <string-name><surname>Ross</surname><given-names>E</given-names></string-name>, <string-name><surname>Iranzadeh</surname><given-names>A</given-names></string-name>, <string-name><surname>Du Plessis</surname><given-names>M</given-names></string-name>, <string-name><surname>Radzey</surname><given-names>N</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>Z</given-names></string-name>, <string-name><surname>Calder</surname><given-names>B</given-names></string-name>, <string-name><surname>Allali</surname><given-names>I</given-names></string-name>, <string-name><surname>Mulder</surname><given-names>N</given-names></string-name>, <string-name><surname>Dabee</surname><given-names>S</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>S</given-names></string-name>, <string-name><surname>Gamieldien</surname><given-names>H</given-names></string-name>, <string-name><surname>Godzik</surname><given-names>A</given-names></string-name>, <string-name><surname>Blackburn</surname><given-names>JM</given-names></string-name>, <string-name><surname>Tabb</surname><given-names>DL</given-names></string-name>, <string-name><surname>Bekker</surname><given-names>LG</given-names></string-name>, <string-name><surname>Jaspan</surname><given-names>HB</given-names></string-name>, <string-name><surname>Passmore</surname><given-names>JS</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name></person-group>. <year>2020</year>. <article-title>Microbial function and genital inflammation in young South African women at high risk of HIV infection</article-title>. <source>Microbiome</source><volume>8</volume>:<fpage>165</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40168-020-00932-8</pub-id>.<pub-id pub-id-type="pmid">33220709</pub-id></mixed-citation>
              </ref>
              <ref id="B61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyssen</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>YY</given-names></string-name>, <string-name><surname>Hayward</surname><given-names>JA</given-names></string-name>, <string-name><surname>Agius</surname><given-names>PA</given-names></string-name>, <string-name><surname>DeLong</surname><given-names>K</given-names></string-name>, <string-name><surname>Aldunate</surname><given-names>M</given-names></string-name>, <string-name><surname>Ravel</surname><given-names>J</given-names></string-name>, <string-name><surname>Moench</surname><given-names>TR</given-names></string-name>, <string-name><surname>Cone</surname><given-names>RA</given-names></string-name>, <string-name><surname>Tachedjian</surname><given-names>G</given-names></string-name></person-group>. <year>2018</year>. <article-title>Anti-HIV-1 activity of lactic acid in human cervicovaginal fluid</article-title>. <source>mSphere</source><volume>3</volume>:<elocation-id>e00055-18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSphere.00055-18</pub-id>.<pub-id pub-id-type="pmid">29976641</pub-id></mixed-citation>
              </ref>
              <ref id="B62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nahui Palomino</surname><given-names>RA</given-names></string-name>, <string-name><surname>Zicari</surname><given-names>S</given-names></string-name>, <string-name><surname>Vanpouille</surname><given-names>C</given-names></string-name>, <string-name><surname>Vitali</surname><given-names>B</given-names></string-name>, <string-name><surname>Margolis</surname><given-names>L</given-names></string-name></person-group>. <year>2017</year>. <article-title>Vaginal Lactobacillus inhibits HIV-1 replication in human tissues ex vivo</article-title>. <source>Front Microbiol</source><volume>8</volume>:<fpage>906</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2017.00906</pub-id>.<pub-id pub-id-type="pmid">28579980</pub-id></mixed-citation>
              </ref>
              <ref id="B63">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Low</surname><given-names>N</given-names></string-name>, <string-name><surname>Chersich</surname><given-names>MF</given-names></string-name>, <string-name><surname>Schmidlin</surname><given-names>K</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Francis</surname><given-names>SC</given-names></string-name>, <string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <string-name><surname>Hayes</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J</given-names></string-name>, <string-name><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>R</given-names></string-name>, <string-name><surname>McGrath</surname><given-names>N</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name><surname>Myer</surname><given-names>L</given-names></string-name>, <string-name><surname>Temmerman</surname><given-names>M</given-names></string-name>, <string-name><surname>van der Straten</surname><given-names>A</given-names></string-name>, <string-name><surname>Watson-Jones</surname><given-names>D</given-names></string-name>, <string-name><surname>Zwahlen</surname><given-names>M</given-names></string-name>, <string-name><surname>Hilber</surname><given-names>AM</given-names></string-name></person-group>. <year>2011</year>. <article-title>Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis</article-title>. <source>PLoS Med</source><volume>8</volume>:<elocation-id>e1000416</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1000416</pub-id>.<pub-id pub-id-type="pmid">21358808</pub-id></mixed-citation>
              </ref>
              <ref id="B64">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van de Wijgert</surname><given-names>JH</given-names></string-name>, <string-name><surname>Verwijs</surname><given-names>MC</given-names></string-name>, <string-name><surname>Turner</surname><given-names>AN</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>CS</given-names></string-name></person-group>. <year>2013</year>. <article-title>Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission</article-title>. <source>AIDS</source><volume>27</volume>:<fpage>2141</fpage>–<lpage>2153</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0b013e32836290b6</pub-id>.<pub-id pub-id-type="pmid">23660575</pub-id></mixed-citation>
              </ref>
              <ref id="B65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vodstrcil</surname><given-names>LA</given-names></string-name>, <string-name><surname>Hocking</surname><given-names>JS</given-names></string-name>, <string-name><surname>Law</surname><given-names>M</given-names></string-name>, <string-name><surname>Walker</surname><given-names>S</given-names></string-name>, <string-name><surname>Tabrizi</surname><given-names>SN</given-names></string-name>, <string-name><surname>Fairley</surname><given-names>CK</given-names></string-name>, <string-name><surname>Bradshaw</surname><given-names>CS</given-names></string-name></person-group>. <year>2013</year>. <article-title>Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e73055</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0073055</pub-id>.<pub-id pub-id-type="pmid">24023807</pub-id></mixed-citation>
              </ref>
              <ref id="B66">
                <label>66</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kourtis</surname><given-names>AP</given-names></string-name>, <string-name><surname>Haddad</surname><given-names>L</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name><surname>Chinula</surname><given-names>L</given-names></string-name>, <string-name><surname>Hurst</surname><given-names>S</given-names></string-name>, <string-name><surname>Wiener</surname><given-names>J</given-names></string-name>, <string-name><surname>Ellington</surname><given-names>S</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>JA</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>A</given-names></string-name>, <string-name><surname>De Paris</surname><given-names>K</given-names></string-name>, <string-name><surname>King</surname><given-names>CC</given-names></string-name>, <string-name><surname>Hosseinipour</surname><given-names>M</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>IF</given-names></string-name>, <string-name><surname>Jamieson</surname><given-names>DJ</given-names></string-name></person-group>. <year>2017</year>. <article-title>A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: addressing evolving research priorities</article-title>. <source>Contemp Clin Trials</source><volume>52</volume>:<fpage>27</fpage>–<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cct.2016.11.006</pub-id>.<pub-id pub-id-type="pmid">27836505</pub-id></mixed-citation>
              </ref>
              <ref id="B67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chinula</surname><given-names>L</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>JAE</given-names></string-name>, <string-name><surname>Wiener</surname><given-names>J</given-names></string-name>, <string-name><surname>Tang</surname><given-names>JH</given-names></string-name>, <string-name><surname>Hurst</surname><given-names>S</given-names></string-name>, <string-name><surname>Tegha</surname><given-names>G</given-names></string-name>, <string-name><surname>Msika</surname><given-names>A</given-names></string-name>, <string-name><surname>Ellington</surname><given-names>S</given-names></string-name>, <string-name><surname>Hosseinipour</surname><given-names>MC</given-names></string-name>, <string-name><surname>Mataya</surname><given-names>R</given-names></string-name>, <string-name><surname>Haddad</surname><given-names>LB</given-names></string-name>, <string-name><surname>Kourtis</surname><given-names>AP</given-names></string-name></person-group>. <year>2018</year>. <article-title>Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial</article-title>. <source>Contraception</source><volume>98</volume>:<fpage>193</fpage>–<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.contraception.2018.05.001</pub-id>.<pub-id pub-id-type="pmid">29746813</pub-id></mixed-citation>
              </ref>
              <ref id="B68">
                <label>68</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kourtis</surname><given-names>AP</given-names></string-name>, <string-name><surname>Wiener</surname><given-names>J</given-names></string-name>, <string-name><surname>Hurst</surname><given-names>S</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>JAE</given-names></string-name>, <string-name><surname>Cottrell</surname><given-names>ML</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>A</given-names></string-name>, <string-name><surname>Chinula</surname><given-names>L</given-names></string-name>, <string-name><surname>Msika</surname><given-names>A</given-names></string-name>, <string-name><surname>Haddad</surname><given-names>LB</given-names></string-name>, <string-name><surname>Tang</surname><given-names>JH</given-names></string-name></person-group>. <year>2019</year>. <article-title>Brief report: HIV shedding in the female genital tract of women on ART and progestin contraception: extended follow-up results of a randomized clinical trial</article-title>. <source>J Acquir Immune Defic Syndr</source><volume>81</volume>:<fpage>163</fpage>–<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAI.0000000000002011</pub-id>.<pub-id pub-id-type="pmid">31095006</pub-id></mixed-citation>
              </ref>
              <ref id="B69">
                <label>69</label>
                <mixed-citation publication-type="webpage"><collab>WHO</collab>. <year>2019</year>. Contraceptive eligibility for women at high risk for HIV. Guidance statement—recommendations on contraceptive methods used by women at high risk of HIV. <comment>WHO, Geneva, Switzerland</comment>. <ext-link xlink:href="https://www.who.int/publications/i/item/9789241550574" ext-link-type="uri">https://www.who.int/publications/i/item/9789241550574</ext-link>.</mixed-citation>
              </ref>
              <ref id="B70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ngcapu</surname><given-names>S</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Sibeko</surname><given-names>S</given-names></string-name>, <string-name><surname>Werner</surname><given-names>L</given-names></string-name>, <string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>, <string-name><surname>Mlisana</surname><given-names>K</given-names></string-name>, <string-name><surname>Shey</surname><given-names>M</given-names></string-name>, <string-name><surname>Samsunder</surname><given-names>N</given-names></string-name>, <string-name><surname>Karim</surname><given-names>SA</given-names></string-name>, <string-name><surname>Karim</surname><given-names>QA</given-names></string-name>, <string-name><surname>Passmore</surname><given-names>JA</given-names></string-name></person-group>. <year>2015</year>. <article-title>Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive</article-title>. <source>J Reprod Immunol</source><volume>110</volume>:<fpage>14</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jri.2015.03.007</pub-id>.<pub-id pub-id-type="pmid">25956139</pub-id></mixed-citation>
              </ref>
              <ref id="B71">
                <label>71</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deese</surname><given-names>J</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Miller</surname><given-names>W</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>M</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>K</given-names></string-name>, <string-name><surname>Agot</surname><given-names>K</given-names></string-name>, <string-name><surname>Crucitti</surname><given-names>T</given-names></string-name>, <string-name><surname>Abdellati</surname><given-names>S</given-names></string-name>, <string-name><surname>Van Damme</surname><given-names>L</given-names></string-name></person-group>. <year>2015</year>. <article-title>Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract</article-title>. <source>Am J Reprod Immunol</source><volume>74</volume>:<fpage>357</fpage>–<lpage>367</lpage>. doi:<pub-id pub-id-type="doi">10.1111/aji.12415</pub-id>.<pub-id pub-id-type="pmid">26202107</pub-id></mixed-citation>
              </ref>
              <ref id="B72">
                <label>72</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haddad</surname><given-names>LB</given-names></string-name>, <string-name><surname>Wall</surname><given-names>KM</given-names></string-name>, <string-name><surname>Kilembe</surname><given-names>W</given-names></string-name>, <string-name><surname>Vwalika</surname><given-names>B</given-names></string-name>, <string-name><surname>Khu</surname><given-names>NH</given-names></string-name>, <string-name><surname>Brill</surname><given-names>I</given-names></string-name>, <string-name><surname>Chomba</surname><given-names>E</given-names></string-name>, <string-name><surname>Tichacek</surname><given-names>A</given-names></string-name>, <string-name><surname>Allen</surname><given-names>S</given-names></string-name></person-group>. <year>2018</year>. <article-title>Bacterial vaginosis modifies the association between hormonal contraception and HIV acquisition</article-title>. <source>AIDS</source><volume>32</volume>:<fpage>595</fpage>–<lpage>604</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000001741</pub-id>.<pub-id pub-id-type="pmid">29334545</pub-id></mixed-citation>
              </ref>
              <ref id="B73">
                <label>73</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sabo</surname><given-names>MC</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>BA</given-names></string-name>, <string-name><surname>Lavreys</surname><given-names>L</given-names></string-name>, <string-name><surname>Martin</surname><given-names>HL</given-names>, <suffix>Jr</suffix></string-name>, <string-name><surname>Jaoko</surname><given-names>W</given-names></string-name>, <string-name><surname>Mandaliya</surname><given-names>K</given-names></string-name>, <string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Overbaugh</surname><given-names>J</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RS</given-names></string-name></person-group>. <year>2019</year>. <article-title>Does bacterial vaginosis modify the effect of hormonal contraception on HIV seroconversion</article-title>. <source>AIDS</source><volume>33</volume>:<fpage>1225</fpage>–<lpage>1230</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000002167</pub-id>.<pub-id pub-id-type="pmid">31048629</pub-id></mixed-citation>
              </ref>
              <ref id="B74">
                <label>74</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sabo</surname><given-names>MC</given-names></string-name>, <string-name><surname>Lehman</surname><given-names>DA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>BA</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Osborn</surname><given-names>L</given-names></string-name>, <string-name><surname>Matemo</surname><given-names>D</given-names></string-name>, <string-name><surname>Kinuthia</surname><given-names>J</given-names></string-name>, <string-name><surname>Fiedler</surname><given-names>TL</given-names></string-name>, <string-name><surname>Munch</surname><given-names>MM</given-names></string-name>, <string-name><surname>Drake</surname><given-names>AL</given-names></string-name>, <string-name><surname>Fredricks</surname><given-names>DN</given-names></string-name>, <string-name><surname>Overbaugh</surname><given-names>J</given-names></string-name>, <string-name><surname>John-Stewart</surname><given-names>G</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RS</given-names></string-name>, <string-name><surname>Graham</surname><given-names>SM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Associations between vaginal bacteria implicated in HIV acquisition risk and proinflammatory cytokines and chemokines</article-title>. <source>Sex Transm Infect</source><volume>96</volume>:<fpage>3</fpage>–<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1136/sextrans-2018-053949</pub-id>.<pub-id pub-id-type="pmid">31197065</pub-id></mixed-citation>
              </ref>
              <ref id="B75">
                <label>75</label>
                <mixed-citation publication-type="webpage"><collab>WHO</collab>. <year>2015</year>. Medical eligibility criteria for contraceptive use, 5th ed. <comment>WHO, Geneva, Switzerland</comment>. <ext-link xlink:href="https://www.who.int/publications/i/item/9789241549158" ext-link-type="uri">https://www.who.int/publications/i/item/9789241549158</ext-link>.</mixed-citation>
              </ref>
              <ref id="B76">
                <label>76</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holm</surname><given-names>JB</given-names></string-name>, <string-name><surname>Humphrys</surname><given-names>MS</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>CK</given-names></string-name>, <string-name><surname>Settles</surname><given-names>ML</given-names></string-name>, <string-name><surname>Ott</surname><given-names>S</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, <string-name><surname>He</surname><given-names>X</given-names></string-name>, <string-name><surname>McComb</surname><given-names>E</given-names></string-name>, <string-name><surname>Gravitt</surname><given-names>PE</given-names></string-name>, <string-name><surname>Ghanem</surname><given-names>KG</given-names></string-name>, <string-name><surname>Brotman</surname><given-names>RM</given-names></string-name>, <string-name><surname>Ravel</surname><given-names>J</given-names></string-name></person-group>. <year>2019</year>. <article-title>Ultrahigh-throughput multiplexing and sequencing of &gt;500-base-pair amplicon regions on the Illumina HiSeq 2500 platform</article-title>. <source>mSystems</source><volume>4</volume>:<elocation-id>e00029-19</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.00029-19</pub-id>.<pub-id pub-id-type="pmid">30801027</pub-id></mixed-citation>
              </ref>
              <ref id="B77">
                <label>77</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuczynski</surname><given-names>J</given-names></string-name>, <string-name><surname>Stombaugh</surname><given-names>J</given-names></string-name>, <string-name><surname>Walters</surname><given-names>WA</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>A</given-names></string-name>, <string-name><surname>Caporaso</surname><given-names>JG</given-names></string-name>, <string-name><surname>Knight</surname><given-names>R</given-names></string-name></person-group>. <year>2012</year>. <article-title>Using QIIME to analyze 16S rRNA gene sequences from microbial communities</article-title>. <source>Curr Protoc Bioinformatics</source><volume>Chapter 10</volume>:<fpage>Unit 10.7</fpage>. doi:<pub-id pub-id-type="doi">10.1002/0471250953.bi1007s36</pub-id>.</mixed-citation>
              </ref>
              <ref id="B78">
                <label>78</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmieder</surname><given-names>R</given-names></string-name>, <string-name><surname>Lim</surname><given-names>YW</given-names></string-name>, <string-name><surname>Rohwer</surname><given-names>F</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>R</given-names></string-name></person-group>. <year>2010</year>. <article-title>TagCleaner: identification and removal of tag sequences from genomic and metagenomic datasets</article-title>. <source>BMC Bioinformatics</source><volume>11</volume>:<fpage>341</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2105-11-341</pub-id>.<pub-id pub-id-type="pmid">20573248</pub-id></mixed-citation>
              </ref>
              <ref id="B79">
                <label>79</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Callahan</surname><given-names>BJ</given-names></string-name>, <string-name><surname>McMurdie</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Han</surname><given-names>AW</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>SP</given-names></string-name></person-group>. <year>2016</year>. <article-title>DADA2: high-resolution sample inference from Illumina amplicon data</article-title>. <source>Nat Methods</source><volume>13</volume>:<fpage>581</fpage>–<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nmeth.3869</pub-id>.<pub-id pub-id-type="pmid">27214047</pub-id></mixed-citation>
              </ref>
              <ref id="B80">
                <label>80</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Garrity</surname><given-names>GM</given-names></string-name>, <string-name><surname>Tiedje</surname><given-names>JM</given-names></string-name>, <string-name><surname>Cole</surname><given-names>JR</given-names></string-name></person-group>. <year>2007</year>. <article-title>Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy</article-title>. <source>Appl Environ Microbiol</source><volume>73</volume>:<fpage>5261</fpage>–<lpage>5267</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.00062-07</pub-id>.<pub-id pub-id-type="pmid">17586664</pub-id></mixed-citation>
              </ref>
              <ref id="B81">
                <label>81</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quast</surname><given-names>C</given-names></string-name>, <string-name><surname>Pruesse</surname><given-names>E</given-names></string-name>, <string-name><surname>Yilmaz</surname><given-names>P</given-names></string-name>, <string-name><surname>Gerken</surname><given-names>J</given-names></string-name>, <string-name><surname>Schweer</surname><given-names>T</given-names></string-name>, <string-name><surname>Yarza</surname><given-names>P</given-names></string-name>, <string-name><surname>Peplies</surname><given-names>J</given-names></string-name>, <string-name><surname>Glockner</surname><given-names>FO</given-names></string-name></person-group>. <year>2013</year>. <article-title>The SILVA ribosomal RNA gene database project: improved data processing and web-based tools</article-title>. <source>Nucleic Acids Res</source><volume>41</volume>(<issue>Database issue</issue>):<fpage>D590</fpage>–<lpage>D596</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gks1219</pub-id>.<pub-id pub-id-type="pmid">23193283</pub-id></mixed-citation>
              </ref>
              <ref id="B82">
                <label>82</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>France</surname><given-names>M</given-names></string-name>, <string-name><surname>Ma</surname><given-names>B</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, <string-name><surname>Brown</surname><given-names>S</given-names></string-name>, <string-name><surname>Humphrys</surname><given-names>MS</given-names></string-name>, <string-name><surname>Holm</surname><given-names>JB</given-names></string-name>, <string-name><surname>Brotman</surname><given-names>RM</given-names></string-name>, <string-name><surname>Ravel</surname><given-names>J</given-names></string-name></person-group>. <year>2020</year>. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. <comment>Research Square</comment><ext-link xlink:href="https://www.researchsquare.com/article/rs-14699/v1" ext-link-type="uri">https://www.researchsquare.com/article/rs-14699/v1</ext-link>.</mixed-citation>
              </ref>
              <ref id="B83">
                <label>83</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>CM</given-names></string-name>, <string-name><surname>Aziz</surname><given-names>M</given-names></string-name>, <string-name><surname>Kachur</surname><given-names>S</given-names></string-name>, <string-name><surname>Hsueh</surname><given-names>PR</given-names></string-name>, <string-name><surname>Huang</surname><given-names>YT</given-names></string-name>, <string-name><surname>Keim</surname><given-names>P</given-names></string-name>, <string-name><surname>Price</surname><given-names>LB</given-names></string-name></person-group>. <year>2012</year>. <article-title>BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay</article-title>. <source>BMC Microbiol</source><volume>12</volume>:<fpage>56</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2180-12-56</pub-id>.<pub-id pub-id-type="pmid">22510143</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
